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Résumé 
 
La majorité des personnes infectées par le virus de l’hépatite C (VHC) développent 
une virémie persistante. Malheureusement, notre connaissance des paramètres de 
l'immunité protectrice est limitée. La génération et la maintenance des cellules T CD4+ et  
T CD8+ spécifiques au VHC et polyfonctionnelles, caractérisées par la sécrétion de 
plusieurs cytokines comme l’IFN-γ, le TNF-α et l’IL-2, sont associées à la résolution 
spontanée du virus. De plus, la présence d’anticorps neutralisants est associée à une charge 
virale plus faible et à une durée de virémie réduite suivant une réinfection. Dans ce projet, 
nous avons l'intention de définir les paramètres de l'immunité protectrice contre le VHC 
chez les personnes s’injectant des drogues (PID) qui ont déjà été infectés par le VHC. Ces 
personnes sont exposées au virus à répétition, mais sont résistantes à une seconde infection. 
En outre, nous avons l’intention de comparer l’immunité protectrice chez les personnes 
ayant résolu leur infection spontanément versus ceux qui ont reçu un traitement antiviral. 
Nous émettons l'hypothèse que les PID résistantes à la réinfection développent une réponse 
immunitaire supérieure, caractérisée par une augmentation de la fréquence de cellules T 
mémoires spécifiques au VHC; du nombre d'épitopes ciblés par ces cellules; du nombre de 
fonctions effectrices par cellule; ainsi qu’une réponse élevée des anticorps neutralisant. En 
utilisant les techniques « Enzyme-linked immunospot » (ELISPOT), le marquage 
intracellulaire des cytokines (ICS), ainsi qu’un test de neutralisation de pseudoparticules 
(HCVpp), nous avons examiné la réponse cellulaire et humorale chez les PID exposées 
mais non-réinfectées versus les PID réinfectées. Nous avons observé une plus grande 
fréquence des cellules T spécifiques au VHC chez les PID qui n’ont pas été réinfectées 
pendant ≥ 2 ans. Nous n’avons pas observé une différence significative pour la 
neutralisation par les anticorps, ni pour la fonctionnalité de cellules T spécifiques. Nos 
résultats suggèrent que la protection contre la réinfection chez les PID est corrélée à une 
haute fréquence de cellules T spécifiques au HCV soutenue dans le temps. 
 
Mots-clés : virus de l’hépatite C (VHC), réinfection, immunité protectrice, vaccins, 
personnes s’injectant des drogues (PID) 
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Abstract 
 
The majority of HCV infected individuals develop persistent viremia. Correlates of 
long-term protective immunity remain undefined. Generation and maintenance of 
polyfunctional CD4 and CD8 HCV-specific T cells that produce multiple cytokines like 
IFN-γ, TNF-α and IL-2 correlates with spontaneous resolution of acute primary HCV and 
can be predictive of long-term protection. The presence of neutralizing antibodies (nAb) 
was associated with reduced magnitude and length of viremia upon reinfection. The aims 
of this project were: 1) to define correlates of protective immunity in HCV-resolved high 
risk people who inject drugs (PWIDs) repeatedly exposed to but resistant to reinfections; 
and 2) to compare protective immune responses in PWIDs with spontaneous versus 
treatment-induced clearance. We hypothesized that PWIDs resistant to reinfections harbor 
an immune response of high magnitude, breadth and quality of the HCV-specific memory 
T cells as well as higher nAb responses. Using IFN-γ enzyme-linked immunospot 
(ELISPOT), intracellular staining for cytokines, and pseudoparticle neutralization assays, 
we examined cellular and humoral immune responses in long-term protected versus 
reinfected PWIDs. We observed long-lived HCV-specific T cell responses in spontaneously 
resolved and treatment resolved PWIDs who are protected against reinfection. We did not 
observe a difference in the nAb responses nor in the functionality of HCV-specific T cells. 
Our results suggest that protection from reinfection in PWIDs is associated with a sustained 
high frequency of HCV-specific cellular immune responses. 
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1.1. Historical Introduction 
 
The hepatitis C virus (HCV) is the causative agent of approximately 185 million 
chronic infections worldwide [1]. The first traces of this virus were documented in 1975 
when twenty-two patients showed symptoms of transfusion-associated hepatitis without 
exhibiting serological markers of hepatitis A and B viruses [2], hence adopting the term, 
non-A, non-B viral hepatitis (NANBH). In the majority of patients, NANBH resulted in 
persistent liver damage and caused liver cirrhosis in 20% of chronically infected patients 
[3]. Following an arduous screening process of millions of bacterial cDNA clones derived 
from experimentally infected chimpanzees, a single HCV clone was discovered by a team 
of scientists lead by Michael Houghton at the Chiron Corporation in 1989 [3]. This 
discovery unveiled the 50-80 nm enveloped positive sense single stranded RNA virus of 
about 10,000 nucleotides [4]. Within the past 25 years, from its discovery to the 
development of effective therapies, significant breakthroughs have been accomplished, 
however HCV prevails as a major global problem as an astounding ≈ 3% of humans remain 
chronically infected [5]. 
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1.2. The virus  
1.2.1. Genome  
 
HCV is a non-cytopathic virus infecting only hepatocytes of humans and 
chimpanzees. The HCV genome is comprised of an uncapped positive single-stranded 
RNA (+ssRNA) of about 9.6 kb-pairs [4]. The genome consists of an uninterrupted open 
reading frame (ORF) encoding a 3000 amino acid polyprotein precursor [4]. Following co- 
and post-translational modifications by cellular and viral proteases, the polyprotein is 
cleaved into three structural (Core, E1, and E2) and seven non-structural (NS) proteins (P7, 
NS2, NS3, NS4A, NS4B, NS5A, NS5B) (Figure 1.1). The ORF is flanked by 5’ and 3’ un-
translated regions (UTRs) that harbour secondary RNA structures important for viral 
replication. The 5’ UTR contains an internal ribosome entry site (IRES) that facilitates the 
initiation of protein translation [6].  
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Figure 1.1.:  Genomic Organization of the HCV Virus. HCV RNA is translated into a 
precursor polyprotein molecule that undergoes further post-translational processing into 
HCV proteins and enzymes.  (Adapted from Abdel-Hakeem et al., 2014 [7]) 
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1.2.2. The viral proteins  
 
 The core protein is the scaffolding unit of the viral nucleocapsid. The E1 and E2 
glycoproteins make contacts with receptors on target cells and mediate entry of the virus. 
E2 harbours hypervariable regions (HVR) that are the targets of neutralizing antibodies 
(nAbs). P7, a small hydrophobic polypeptide, acts as a viroporin or ion channel. The NS2 
protein bears an autoprotease activity essential for the cleavage of the HCV polyprotein 
between NS2 and NS3. NS3 is a multifunctional protein, and together with the cofactor 
NS4A, act as an NS3-NS4A serine protease that catalyzes the processing of the HCV 
polyprotein. NS3 also possesses RNA helicase/NTPase activity that loosens RNA-RNA 
substrates and is vital for RNA replication. The functions of NS4B and NS5A are not well 
defined. However, some evidence suggests that NS4B causes the formation of a 
membranous web wherein viral replication is allowed to take place [8]. NS5A was 
suggested to have an important role in enhancing viral replications [9, 10] and was also 
shown to contain a region important for alpha interferon (IFN-α) therapy susceptibility 
known as the interferon sensitivity-determining region (ISDR) [11]. NS5B is the viral 
RNA-dependent RNA-polymerase (RdRp) that allows HCV-RNA replication [6]. The 
HCV RdRp enzyme has an absence of proofreading ability and is consequently error prone, 
resulting in the emergence of varying viral populations present in a patient’s blood as a 
mosaic of related sequences, collectively termed “quasispecies” [6] 
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1.2.3. Classification and Genetic variability 
 
The HCV virus is classified under the Hepacivirus genus within the Flaviviridae 
family, which also encompasses the yellow fever, dengue and the west Nile virus [4]. HCV 
shows extensive genetic diversity and is classified into seven genotypes (1-7) based on 
phylogenetic and sequence analysis of the viral genome [12]. These different genotypes 
diverge at approximately 30-35% of nucleotide sequences. In addition, each genotype is 
further subdivided into 67 confirmed subtypes, and strains in the same subtype differ at 
less than 15% of nucleotide sites [13]. Interestingly, it is well established that genotypes 
show geographically variance, and certain genotypes such as subtypes 1a, 1b, 2a and 3a 
are extensively spread across the globe and are endemic in high-income countries [14].   
 
 
 
 
 
 
 
 
 
  
7 
1.2.4. HCV Life Cycle 
 
Figure 1.2. Summary of HCV replication cycle. The HCV lipoviral particle (LVP) 
anchors to SRB1 and CD81 as well as claduin-1 and occluding and enters the cell via 
receptor-mediated endocytosis. Following internalization and fusion of the viral envelope 
with endosomes, the viral genome is uncoated and released into the cytoplasm. In the ER, 
the viral RNA is translated and the HCV polyprotein is produced and cleaved into mature 
structural and non-structural (NS) proteins. In collaboration with host factors, viral NS 
proteins form a membranous web wherein viral replication takes place. Viral assembly is 
suggested to take place in proximity the ER. Lastly, HCV particles are secreted into the 
extracellular environment through the secretory pathway. (Adapted from Wong et al.. 2016 
[15]) 
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1.2.4.1. Virus Composition and Viral Entry  
 
HCV virions are 50-80 nm in diameter and contain a single-stranded (ss) RNA 
genome [16]. The genome is enclosed by a nucleocapsid composed of core protein. The 
nucleocapsid is then enclosed within a lipid membrane that constitutes the viral envelope. 
The envelope glycoproteins E1 and E2 are anchored within the lipid-laden viral envelope. 
The HCV virion is closely associated with lipoproteins and apolipoproteins such as apoE 
and apoB. The lipid composition of the viral envelope is similar to very-low density 
lipoproteins (VLDL) and low-density lipoproteins (LDL) and cholesteryl esters make up 
for approximately half of total HCV lipids [17]. The E1 and E1 envelope glycoproteins 
play an essential role in receptor attachment and mediate the fusion between the viral 
envelope and the target cell membrane.  
During the onset of an HCV infection, HCV virions are transported by the blood 
and after crossing the endothelium of liver sinusoids, they establish direct contact with the 
basolateral surface of hepatocytes in the space of Disse. The first attachment of HCV 
particles onto hepatocytes is made possible by the heparin sulfate proteoglycan syndecan-
1 or syndecan-4 [18, 19] or by the scavenger receptor B1 (SRB1) [20]. The steps 
immediately following the initial attachment of the virion are partially understood and are 
thought to involve four important cellular factors. Among these are SRB1, tetraspanin 
CD81, tight-junction protein claudin-1 (CLDN1) and occludin (OCLN) [21]. It has been 
suggested that SRB1 may be the first entry factor that interacts with the virion after cell 
attachment due to its dual interaction with E2 and lipoproteins. An interesting hypothesis 
the remains to be confirmed is that SRB1 modifies the lipid composition of the virion 
enabling the unveiling of the CD81 binding site on the E2 glycoprotein [20, 22]. HCV is 
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endocytosed in a clathrin-dependent process into Rab5a positive early endosomes where 
fusion takes place. Once released into the cytosol, the HCV genome is translated to produce 
viral proteins and start viral replication. Interestingly, in the liver of HCV patients, infected 
cells are found in clusters, therefore suggesting that cell-to-cell spread accounts for the 
main mechanism of HCV transmission. The exact mechanisms governing this mode of 
transmission remain to be investigated, but may implicate the role of exosomes [23]. 
1.2.4.2. Translation and replication  
 
HCV RNA translation begins with the aid of cellular factors [24]. The main 
outcome of HCV ORF translation is a single large polyprotein that is subsequently cleaved 
and processed into 10 mature proteins mentioned earlier. The junctions between the 
structural proteins are cleaved by host signal peptidases from the ER [6]. NS3 performs the 
cleavage of NS4A from itself and NS4B. NS4A then partners with NS3 resulting in the 
NS3/NS4A complex ready to cleave at the NS4B/5A and NS5A/NS5B junctions. The 
NS2/3 autoprotease achieves the cleavage between NS2 and NS3 [25]. 
Once translation is complete, the HCV proteins are associated with endoplasmic 
reticulum-derived membranes. Collectively, the NS3/4A, NS4B, NS5A, NS5B proteins 
comprise the viral proteins of the replication machinery, that is responsible for replicating 
the positive sense RNA genome from a negative strand intermediate [26]. The NS5B RdRp 
is the principal enzyme for RNA synthesis and HCV replication is dependent on a liver-
specific microRNA (miR) called miR-122 that recruits the Argonaute (Ago) 2 protein to 
the 5’ end of the viral genome [27]. This attachment of Ago to the viral genome retards the 
degradation of the HCV genome by the 5’ exonuclease Xrn1 [28].  
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1.2.4.3. HCV Virion Assembly and Release 
 
 The morphogenesis of the HCV virion requires the aggregation of viral structural 
proteins and genomic RNA that are brought to proximity in a timely and spatially organized 
condition [29]. It is difficult to detect assembling, budding, or egressing virions in infected 
cells, implying that these mechanisms are either rare or extremely rapid. An interesting 
peculiarity of HCV assembly is its close connection to the lipid metabolism pathway.  An 
important component of the viral particle is the core protein, which constitutes the 
nucleocapsid harbouring the HCV genome. Upon synthesis and cleavage in the ER 
membrane, the core protein homodimerizes [30] and is then displaced to lipid droplets 
(LDs) [31, 32]. This interaction between the core protein and the LDs is suggested to be 
imperative for the recruitment of other key components in HCV assembly [33].  
 Another crucial component of the HCV virion is the envelope glycoprotein complex 
whereby E1 and E2 glycoproteins form a non-covalent heterodimer in the ER [34] that 
needs to migrate close to the LDs where assembly occurs [33]. It has been reported that 
NS2 interacts with E1, E2 and p7, establishing essential interactions for the migration of 
the E1E2 heterodimer to the virion assembly site [35-38]. The disulphide bridges between 
E1 and E2 at the surface of the HCV virion are suggested to play an active role in the 
budding step of the HCV particle [39].  
 HCV particle biogenesis is believed to have a close connection the VLDL assembly 
pathway. It has been reported that blocking microsomal triglyceride transfer protein 
(MTP), a protein implicated in VLDL biogenesis, inhibits the formation of HCV viral 
particles [40-42].  
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 The endosomal-sorting complex required for transport (ESCRT) pathway has been 
suggested to have a key role in HCV budding [43-45]. The ESCRT pathway is involved in 
the budding and the fission of vesicles out from the cytoplasm, and is exploited by many 
enveloped viruses for their release from infected cells [46].  
 Once assembly and budding have been completed in the ER, HCV particles transit 
through the secretory pathway and are released from infected cells [47]. In this process, the 
HCV virions attain their particular low buoyant density [40, 48]. Lastly, during egress, it 
is believed that HCV virions are dependent on p7 for neutralizing the acidic compartments 
within the secretory pathway [49].  
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1.2.5. Difficulties in Studying HCV and Experimental Models 
 
Humans and chimpanzees are the only two species that can be infected with HCV. 
Early studies of HCV immunity used the chimpanzee model to generate important findings 
as the timing and dynamics of infection can be controlled, and hepatic tissues could be 
isolated. However, research using chimpanzees is now restricted, forcing scientists to 
innovate newer models to probe further investigations.  
1.2.5.1. In vitro Models 
 
1.2.5.1.1. Huh-7 cells and replicons 
 
The HuH-7 cell line, isolated from an HCC tumour of a Japanese man, proved to 
be instrumental in the early HCV research [50]. This cell line was used to create a replicon 
that could express and replicate HCV RNA continuously. This development of a stable cell 
line expressing the HCV RNA genome was indeed a remarkable achievement as it allowed 
for drug screening and discovery of potent direct-acting antivirals against HCV [51]. 
Despite this major advancement, this replicon model lacked the ability to be a fully 
infectious model in vitro. It was reported that the increased replication rate of the replicon 
was conferred by mutations in the HCV genome, which rendered it incapable of producing 
infectious virions in chimpanzees [52]. Consequently, it was agreed upon that the optimal 
method to develop an in vitro model would focus on wild type HCV genomes. Finally in 
2005, the first successful attempt at generating an infectious in vitro model of HCV 
infection was achieved with the discovery of the Japanese fulminant hepatitis 1 (JFH1) 
genotype 2a clone. This viral strain was obtained from a Japanese patient having developed 
fulminant hepatitis [53]. Upon transfection of this newly isolated strain into HuH-7.5 cells, 
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infectious HCV virions were produced and could be used to infect chimpanzees [54]. In 
2006, more infectious isolates were developed for HCV genotype 1a [55] as well as for 
genotypes 1b, 3a and 4a [56, 57].  
1.2.5.1.2 HCV pseudoparticles (HCVpp) 
 
 Lentiviruses easily forms pseudotypes with the envelope proteins of countless 
viruses [58]. Accordingly, HCV pseudoparticles (HCVpp) developed from an HIV 
backbone expressing HCV glycoproteins are infectious for hepatocytes and hepatoma cell 
lines [58, 59], and facilitated research on HCV entry as well as measuring nAb responses 
for the first time. The infectivity of HCVpp is pH-dependent and can be neutralized by 
many E2-specific mAbs.  
1.2.5.1.3. Primary human hepatocytes (PHH) 
 
PHHs are considered the gold standard for studying hepatocyte function. These 
normal cells are isolated from adjacent tumour tissue in patients undergoing liver resection. 
PHHs can also be obtained from the fetal livers of aborted embryos and can serve as the 
substrate for infection with HCV [60]. Once plated, PHHs do not divide and have a limited 
lifespan of approximately 1-2 weeks. Several studies have observed productive infection 
of PHHs after culture, including cells from HCV-infected patients [61-63].  
1.2.5.2. In vivo Models 
 
Due to the asymptomatic nature of acute HCV infection, a very small number of 
patients seek medical consultation in the acute phase. Consequently, it is not possible to 
determine the exact date of infection or exposure and to figure out the exact infecting strain 
of virus. The majority of the early knowledge of acute infection is derived from chimpanzee 
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experiments or from studies following high-risk exposures such as needle-stick accidents 
in health care workers and blood transfusions, and the rare cases of symptomatic acute 
HCV. There have also been important efforts in establishing cohorts for the monitoring of 
high-risk individuals such as people who inject drugs (PWIDs) who represent the main 
reservoir of HCV in developed countries.  
1.2.5.2.1. Mouse models 
 
The generation of a successful mouse model for the study of HCV has been slow 
and difficult as compared to other hepatic viruses such as HBV. Mouse hepatocytes are a 
poor model for HCV infection due to the differences in many host factors present in human 
hepatocytes [64]. To overcome the hurdle of this species-specific phenomenon, humanized 
mice were generated through the xenotransplantation of PHHs. For this system to be 
effective, the mouse has to be immunodeficient for it to accept human PHHs and replace 
the normal mouse hepatocytes. The first successful use of this strategy was attained in the 
severe combined immunodeficiency (SCID) mice carrying a transgene activated by a liver-
specific albumin promoter [65]. Expression of this transgene allows for acute 
hepatotoxicity, which can then be rescued by the transplantation of injected PHHs, the 
target for inducing HCV infection [65]. Another model wherein hepatotoxicity can be 
controlled consists of using Fah-knockout mice where the liver stays healthy with the 
administration of a molecule called NTBC. When this molecule is no longer administered, 
mice hepatocytes develop toxicity and PHHs can be implanted into the mice liver.  
Moreover, another strategy to develop humanized mice requires genetically adding human 
genes to express human entry factors required for HCV infection. With the discovery of 
HCV entry factors CD81 and occludin, mice were engineered to express human 
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homologues of these proteins and viral entry was reported for the first time in a proof-of-
concept study [66]. Subsequently, HCV infection was successfully reported in a follow-up 
study [67], however, viral replication was low and the mice failed to develop liver disease, 
indicating that this model does not fully exemplify an HCV infection. Another group used 
a similar approach in mice with a different genetic background and were able to achieve 
sustained viremia with progression to fibrosis and cirrhosis [68], suggesting a more 
promising model.  
Humanized mouse models may constitute a reasonable substitute to chimpanzees 
and additional efforts are required to replicate the natural history of human immune 
responses to HCV [69]. These mouse models may also be useful to test vaccine efficacy 
and more efforts are needed to expand their use in the vaccine community [70].  
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1. 3. The disease  
 
1.3.1. Epidemiology 
 
 
 
Figure 1. 3: The estimated prevalence of HCV infection and the global distribution of 
HCV genotypes. The highest prevalence rates of HCV are in Egypt, Pakistan, Greece, and 
Russia. (Adapted from Hajarizadeh et al., 2013[71])  
 
 
 
  
17 
 
The HCV virus infects approximately 180 million individuals are worldwide, which 
translates to a 3% prevalence worldwide [1].  HCV distribution across countries can range 
from <1 % to more than 10% [72, 73]. The highest number of infections is in the developing 
countries of Africa and the Middle East, whereas higher income countries such as the 
Americas, Australia, Northern and Western Europe have a lower prevalence [72, 73]. Egypt 
and Cameroon have the highest prevalence of HCV at > 10% of the population [74, 75]. 
The countries with the highest absolute numbers of HCV infections are China (29.8 
million), India (18.2 million), Egypt (11.8 million), Pakistan (9.4 million) and Indonesia 
(9.4 million) [72].  
1.3.2. Transmission  
 
HCV is most efficiently transmitted by percutaneous exposure to contaminated 
blood, such as by blood donation, hemodialysis and injection drug use [76, 77]. HCV 
transmission from mother to child is rare (2% to 10%) [78]. The exact details are not 
known, however maternal HIV co-infection, ruptured membranes and/or high HCV RNA 
levels augment the risk of transmission [78, 79].  The predominant mode of transmission 
in developed countries such as USA, Australia and Europe is through intravenous drug use 
[80]. In Canada, between 70 and 80% of newly acquired acute HCV infections are 
attributable to injection drug use [81]. Conversely, in developing countries, the majority of 
transmissions of HCV occur through iatrogenic exposure. For example, the main source of 
the HCV surge in Egypt was due to unsafe mass parenteral therapy campaigns against 
schistosomiasis from 1920s to 1980s [82]. 
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1.3.3. Natural history of HCV infection  
 
 An unfortunate feature of HCV infection is its predisposition to establish a chronic 
infection. Nearly 70% (55-85%) of acute infections progress to a persistent infection [83]. 
Moreover, HCV has an extremely rapid turnover with a half-life of 3 hours, generating up 
to 1012 virions daily [84], resulting in exponential serum titres by the end of the first week 
of infection [85, 86]. Furthermore, physical manifestations such as jaundice only result in 
one third of acute infections, leaving the rest of the patients largely asymptomatic and 
undiagnosed for years until serious liver disease symptoms become apparent [87]. Due to 
its asymptomatic nature, the spread of infection and loss of opportunity for early 
intervention are major consequences.  
 Approximately 20% of chronically infected HCV patients develop end-stage 
cirrhosis, liver failure and hepatocellular carcinoma (HCC) [88], comprising a quarter of 
the worldwide cirrhosis and HCC cases [89]. Accordingly, HCV is the most frequent cause 
of liver transplantation (40-50%) [90]. As HCV is a non-cytopathic virus, several reports 
investigated its contribution to the immunopathogenesis of the liver. Proposed mechanisms 
include direct cytotoxic T lymphocyte (CTL)-mediated killing of hepatocytes [91], and 
continuous secretion of inflammatory cytokines resulting in tissue impairment [92]. 
Chronic HCV is also linked to metabolic dysfunction such as insulin resistance, type 2 
diabetes, lipid disorder, and steatosis [93]. Suggested mechanisms for metabolic 
dysfunction consist of the down-regulation of hepatocyte insulin receptor substrate 1 [94] 
as well as the glucose transporter, and the increased expression of PP2A [95]. 
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1.4. The Immune Response to HCV 
1.4.1. Innate Immunity 
 
The innate immune system is the host’s first line of defense against viral infections 
whereby the interferons (IFNs) are produced for mounting an antiviral state in infected 
cells [96]. Depending on their antiviral properties, IFNs are divided into three classes: type 
I, type II and type III IFNs [97]. In humans, type I IFNs consist mainly of IFN-α and IFN-
β [98]. IFN-α and IFN-β target viruses directly by blocking viral replication or indirectly 
by generating innate immune responses [97]. IFN-γ is the only member of the type II IFN 
group and unlike type I IFNs that are induced directly in response to viral infection; IFN-γ 
is secreted by NK cells as well as mitogenically activated T cells [97]. It has been 
demonstrated that IFN-γ downregulates claudin-1 and CD81, thereby inhibiting HCV 
infection [99]. Type III IFNs are comprised of three members including IFN-λ1 (IL-29), 
IFN-λ2 (IL-28A) and IFN-λ3 (IL-28B). Similar to Type I IFNs, type III IFNs are also 
directly activated by viral infection and are secreted mainly in the liver during HCV 
infection [97]. In addition to infected hepatocytes, type I and type III IFNs can also be 
secreted by Kupffer cells [100], BDCA3+ myeloid cells [101] and as plasmacytoid DCs 
(pDCs) [102, 103].  
The innate immune response begins with the recognition of foreign RNA molecular 
patterns shared by related pathogens, called pathogen-associated molecular patterns 
(PAMPs) by pattern recognition receptors (PRRs) including TLRs and intracellular nucleic 
acid binding proteins [104-106]. Upon HCV entry into hepatocytes, the main PRRs that 
are activated are TLR3, protein-kinase R (PKR), and retinoic-acid-inducible gene I (RIG-
I). Signalling through TLR3 is relayed through the TIR domain-containing adapter 
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inducing IFN (TRIF), while PKR and RIG-I signalling is relayed via the mitochondrial 
antiviral signalling protein (MAVS) [107]. These adaptor proteins lead to signalling 
cascades ultimately inducing the secretion of type I IFNs [107]. The auto- and paracrine 
binding of type I IFNs to their cognate receptors relays signalling via the JAK-STAT 
pathway which ultimately leads to the expression of hundreds of ISGs within the infected 
and neighbouring cells [108]. The expression of ISGs establishes a general antiviral state 
in the liver whereby HCV RNA replication and cell-to-cell viral spread is restricted [106]. 
Certain ISGs expressed in response to HCV are proteins with known antiviral effects; 
however, certain others are known to promote HCV replication in vitro, such as ISG15 and 
USP18 [109, 110]. The induction of ISGs in the liver is observed early following HCV 
infection regardless of the outcome of infection, implying that most HCV strains are 
resistant to antiviral effects of this primitive innate response [111-114]. Type III IFNs also 
generate ISGs similar to those induced by Type I IFNs in addition to distinct ISGs [115, 
116]. 
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1.4.1.1. Natural Killer (NK) Cells 
 
 NK cells constitute one of the earliest defenses of the innate immune response. 
Their main function consists of killing virally infected cells through the secretion of 
cytotoxic molecules such as granzymes and perforin, or via TNF-related apoptosis-
inducing ligand (TRAIL)-mediated killing. In addition, NK cells can also secrete cytokines 
regulating innate and adaptive immunity such as IFN-γ, TNFα, IL-10 and IL-21. The 
activation of NK cells is controlled by the calibration of inhibitory and activating signals. 
The strength of the interactions between inhibitory KIRs expressed on NK cells and their 
MHC class I ligands expressed on target cells is the main determinant of NK activity [117].  
 NK cells are ubiquitous within the liver and execute an important role in defending 
against hepatotropic infections [118, 119]. The early activation of NK cells following an 
accidental exposure to HCV in healthcare workers was suggested to contribute to 
protection in 11/12 workers who remained aviremic [120]. In high risk PWIDs, the 
activation of NK cells and expression of the activating receptor NKp30 was associated with 
protection from HCV infection [121]. Furthermore, genetic studies revealed that KIR2DL3 
expressing NK cells secreted more IFN-γ and that homozygosity for this allele correlated 
with spontaneous resolution of HCV infection [122]. Another report demonstrated that 
PWIDs resistant to HCV infection have an enrichment in KIR2DL3+NKG2A- NK cells. 
NKG2A is an inhibitory receptor and binds to HLA-E which is highly expressed during 
HCV infection. This suggests that low expression of NKG2A is advantageous in the 
presence of high HLA-E expression. Overall, KIR2DL3+NKG2A- NK cells are not 
susceptible to HLA-E-mediated inhibition and may explain the ‘natural resistance’ to HCV 
in PWIDs [123].  
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1.4.1.2. Dendritic Cells (DC) 
 
 Dendritic cells are the dominant antigen-presenting cells (APCs) in humans. They 
play a crucial role in bridging innate and adaptive immunity and also impact the priming 
of HCV-specific immune responses. DCs promptly differentiate into mature DCs following 
the sensing of danger signals through PAMPs, particularly TLR ligands, interactions with 
innate lymphocytes (NK and NKT cells), cytokines and other mediators of inflammation 
[124]. Myeloid DCs (mDCs) and plasmacytoid DCs (pDCs) are the two major subsets of 
DCs and both play a role in HCV infection. mDCs account for the majority of DCs and are 
responsible for antigen processing and presentation, whereas pDCs sense viral infections 
and produce type I and type III IFNs. Additionally, pDCs can sense HCV RNA in a TLR-
7 dependent manner when presented by an infected cell [102]. Therefore, DCs are regarded 
as a principal coordinator of the HCV innate and adaptive immunity.  
 The functional role of DCs in acute and chronic HCV continues to be controversial. 
Certain studies have demonstrated that the frequencies of mDCs and pDCs correlate with 
the outcome of infection whereby decreased frequencies were associated with chronic 
infection [125-128]. It was also reported that constant hyper-responsive DCs correlate with 
spontaneous clearance of HCV, implying a superior priming of HCV-specific T cells [129]. 
Moreover, DCs have been shown to be defective in chronic HCV particularly in response 
to TLR ligands [130-133] and may cause the proliferation of Tregs [134].   
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1.4.2. Adaptive immunity 
 
Unlike the innate arm of the immune system which is induced within a short period 
of time (hours to days) after Hepatitis C infection, the adaptive arm requires 6-8 weeks for 
its induction, a phenomenon that is still poorly understood. The adaptive immune system 
comprises of two important components involved in viral clearance, namely T cell 
responses and humoral antibody responses [135].  
1.4.2.1. Humoral Responses  
 
 Despite HCV RNA reaching high blood titres by 2 weeks post-infection, anti-HCV 
antibodies (seroconversion) are largely absent before week 8 [136, 137]. Initial reports 
showed that antibodies (Abs) directed at the HVR-1 region of the HCV E2 glycoprotein 
are neutralizing both in vitro and in vivo [138, 139]. Meanwhile, studies in chimpanzees 
demonstrated that Ab responses did not inherently correlate with viral clearance [140, 141]. 
In humans who spontaneously cleared HCV infection, Ab responses were reported to be of 
delayed onset, bearing low titers and fading rapidly [142-144]. One interesting study 
described how neutralizing Abs (nAbs) emerged in patients only once HCV had established 
a chronic infection, consequently failing to eradicate the virus and selecting for escape 
mutants [145].  Conversely, another study demonstrated that the early appearance of nAbs 
correlated with spontaneous clearance of a primary HCV infection [146].  
 A major obstacle in elucidating humoral immunity against HCV remains that lack 
of optimal tools to measure accurate levels of nAbs. The current approach determines 
neutralization of HCV pseudoparticles (HCVpp) displaying HCV E1-E2 envelope 
glycoproteins that correspond to small number of HCV reference sequences, and 
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unfortunately do not represent all the autologous E1-E2 sequences present in a patient [58, 
59]. An HCVpp library consisting of 19 distinct sequences representing the natural 
variability of E1-E2 glycoprotein of genotype 1 strain was developed to show the evolution 
of the HVR-1 sequences in response to nAbs [147]. Applying this HCVpp library, a study 
demonstrated that clearance of HCV infection correlated with robust induction of nAb 
response mounted early in the infection [148].  
 There are three main hurdles in inducing a protective humoral response against 
HCV. Firstly, HCV envelope proteins (E1-E2) are not strongly immunogenic, leading to 
weak and late Ab response in primary infection [147]. Secondly, due to most Abs targeting 
the HVR of E2, a mutation-prone region, there is a high tendency for the selection of viral 
sequences bearing resistance to Ab neutralization [149]. Lastly, high glycosylation and 
association with host lipoproteins of epitopes targeted by nAbs, shield their visibility and 
restrict their efficacy in vivo [150].  
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1.4.2.2. Cell-Mediated Immunity (CMI) 
 
The significance of CMI in the clearance of HCV is made evident by the correlation 
of specific HLA class I and class II alleles and spontaneous clearance and emphasized by 
depletion studies in the chimpanzee model demonstrating that both CD4+ and CD8+ T 
cells are necessary for viral clearance [151, 152]. CD8+ T cells mediate target cell killing 
by displaying viral antigens on the MHC class I molecules whereas CD4+ T cells mediate 
a helper role in priming and assisting cytotoxic CD8+ T cell (CTL) responses [152].  
1.4.2.2.1. CD8+ T cell response in HCV infection 
 
The number of epitopes targeted by CD8+ T cells, known as breadth, is an important 
factor in the spontaneous resolution of HCV infection. Up to nine unique epitopes were 
recognized by CD8+ T in the acute resolving HCV in humans as well as in chimpanzees, 
whereas few epitopes were targeted in chronic progressors [153, 154]. The NS proteins 
were shown to be immunodominant and correlated with clearance of the virus [155].  
The magnitude of HCV-specific CD8+ T cells correlates with spontaneous 
resolution. Using MHC class I tetramers, it was reported that T cells specific for one epitope 
can attain up to 8% of total CD8+ T cells in spontaneous resolvers [153, 156]. Ex vivo 
phenotypic characterization of HCV-specific CD8+ T cells was also accomplished using 
MHC class I tetramers. It was demonstrated that the primitive expression of the IL-7 
receptor alpha (CD127) on the surface of HCV-specific CD8+ T cells was a key predictor 
of viral clearance and the lack thereof was correlated with viral persistence [157, 158]. 
Meanwhile, during acute infection, PD-1 is variably expressed HCV-specific CD8+ T 
cells, indicating that it is an activation marker instead of an exhaustion marker [159, 160]. 
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Additional exhaustion markers such as T cell immunoglobulin and mucin domain 3 (Tim-
3), cytotoxic T lymphocyte associated antigen-4 (CTLA-4), CD160, KLRG-1 and 2B4 are 
expressed at varying levels in acute and chronic HCV indicating a range of exhaustion that 
is associated with chronic infection [161, 162]. 
The presence of HCV-specific CD8+ T cells in the liver and blood and presence of 
IFN-γ, CD3, CD4, and CD8 mRNA levels in the liver are kinetically associated to a 
decrease in viremia [113, 114].  However, they become challenging to detect in the 
peripheral blood in chronically progressing infections, albeit being easily detectable in the 
liver, displaying an exhausted and activated phenotype [163, 164]. Furthermore, peripheral 
blood HCV-specific CD8+ T cells are suggested to be somewhat defective in their 
proliferative and cytokine producing potential upon initial appearance in the blood [165]. 
Nevertheless, screening of simultaneous effector functions revealed the existence of a 
polyfunctional population of HCV-specific CD8+ T cells concurrently secreting IFN-γ, T 
cell growth factor, IL-2, and expressing the degranulation marker CD107a, a substitute 
marker of cytotoxicity [156]. Further experiments on sorted cells revealed that 
polyfunctionality was specific to CD127+ tetramer-positive CD8+ T cells, reiterating the 
significance of this T cell subset in resolving viremia [156]. Furthermore, it was reported 
that early administration and subsequent SVR to IFN therapy recovers CD127+ long-lived 
memory T cells [156, 166]. 
As HCV infection progresses, noteworthy differences in the CD8+ T cell functions 
are observed coupled with the loss of helper CD4+ T cell responses. In chronically 
progressing patients, continuous loss of function, diminished polyfunctionality and 
decreased proliferative capacity are manifest in CD8+ T cells [156, 167]. CD8+ T cell loss 
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of function is concomitant with their extent of exhaustion and is reversible upon in vitro 
blockade of inhibitory pathways such as PD-1- CTLA-4, and/or TIM-3 [168]. Nonetheless, 
there is a limited efficiency upon in vivo blockade of PD-1 in chronic humans and 
chimpanzees, indicating that a threshold of functional virus-specific T cells is necessary 
for the aforementioned approaches to be successful [169, 170].  This loss of function was 
suggested to be a result of antigen persistence, as demonstrated in the LCMV model 
whereby continuous exposure to viral antigens was the key source of diminished frequency 
and defective effector functions of LCMV-specific CD8+ T cells [171, 172].  
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1.4.2.2.2. CD4+ T cell response in HCV infection 
 
The importance of HCV-specific CD4+T cells was first reported when patients with 
spontaneously clearing HCV mounted broad CD4+ T cell responses during acute infection 
with increased T cell proliferation and IL-2, IFN-γ, and TNF-α production compared to 
patients who developed a persistent infection [173-176]. The significance of CD4+ T cell 
help in sustaining a functional CD8+ T cell response was proven by in vivo chimpanzee 
studies whereby the depletion of CD4+T cells resulted in a gradual decline in the frequency 
of CD8+ T cells and their cytokine production capacity as well as an increase in escape 
mutation is targeted CD8+T cell epitopes [151].  Furthermore, it has been demonstrated 
that the specific expansion of CD161hiCCR6+CD26+ CD4+ T cells expressing IL-17A, IL-
21 and Th17 cell lineage-specific transcription factors have an important correlation with 
the course of the infection [161]. The plasma concentration of IL-17A are higher during 
the acute phase of infection in patients who spontaneously resolve their infection compared 
to their chronic counterparts [161]. A similar trend in IL-21 concentration is apparent a few 
weeks later and correlates with increased HCV-specific CD8+T cells, rescuing them from 
Tim-3/galectin-9 (Gal-9) -mediated apoptosis [161]. Furthermore, IL-21 is a signature 
cytokine of T follicular helper (Tfh) cells, a subtype of CD4+ T cells involved in providing 
maturation signals to B cells for antibody production [177]. Interestingly, HCV-specific-
Tfh cells have been reported to accumulate in the liver and produce more IL-21 compared 
to their peripheral blood counterparts in HCV infected patients. However, the functional 
role of liver-resident HCV-specific Tfh cells in HCV immunity requires further 
investigation [177].  
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When broad CD4+ T cells are detectable in the acute phase in chronically 
progressing patients, these T cells suffer rapid exhaustion followed by consecutive loss of 
IL-2 production, proliferation and IFN-γ production [178, 179] as well as higher expression 
of TIM-3, PD-1 and CTLA-4 [180]. Lastly, it has been demonstrated that chronically 
evolving patients have an expansion of Gal-9 expressing regulatory T (Treg) cells as well 
as higher Gal-9 plasma concentrations, suggesting that binding of Gal-9 to Tim-3 blocks 
IL-21 production by HCV-specific Th17 cells [161].  
1.4.2.2.3. Memory cell-mediated immunity and reinfection 
 
 A landmark study by Mehta et al. reported that patients who were previously 
infected with HCV and spontaneously cleared the virus were 12 times less prone to develop 
persistent viremia [181]. This may be attributable to the robust memory T cell population 
generated in subjects who successfully resolve their infection [182]. Another important 
study followed up a group of women many years after an accidental exposure to an identical 
strain of virus. Interestingly, HCV-specific CD4+ and CD8+ T cell responses were 
detectable up to 20 years after the successful clearance of primary infection in these women 
[183]. Among spontaneous resolvers, phenotypic characterization of HCV-specific CD4+ 
and CD8+ T cells identified the expression of CCR7+, a lymphoid homing marker, and 
CD45RO, both markers associated with memory T cells [184, 185]. Furthermore, in 
spontaneously resolving chimpanzees re-challenged with heterologous HCV isolates, 
duration of viremia was significantly decreased and associated with a high frequency IFN-
γ secreting CD4+ and CD8+ T cells [185-188]. Additional investigation into the role of 
memory T cells was carried out using antibody-mediated depletion of either CD4+ or 
CD8+ T cells in chimpanzees. Depletion of CD4+ T cells led to low viremia levels where 
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CD8+ T cells were able to partially control the infection [151]. However, depletion of 
CD8+ T cells resulted in a considerable delay in the control of viremia, wherein re-
appearance of CD8+ T cells coincided with viremia control [152]. In summary, the 
aforementioned studies highlight the significance of memory T cells in mediating 
protective immunity in reinfection. Importantly, this protective immunity acts to mainly 
reduce the duration and level of viremia in lieu of conferring ‘sterilizing-immunity’ [137]. 
1.4.3. Genetic Factors and Outcome of Acute HCV  
 
In addition to the genetic influence of NK cell receptors mentioned earlier, three 
separate genome-wide association studies (GWAS) published reported an association 
between several single-nucleotide polymorphisms (SNPs) near the IFNλ3 (IL28B) gene 
locus and response to IFN therapy and spontaneous clearance of infection [189-192]. The 
C/C genotype at the SNP rs12979860 strongly correlates with spontaneous clearance of 
primary HCV infection among patients of both European and African backgrounds [189]. 
Furthermore, an RNA sequencing study performed in PHHs revealed a new gene variant 
upstream of IL28B called ss469415590 which creates a new gene called IFNλ4. The IFNλ4 
was reported to be more predictive of HCV viral clearance compared to IFNλ3 in African 
subjects. [193]. 
The exact mechanism for how the IL28B SNPs impact HCV outcomes are 
unknown, however, it is well established that IL28A, IL28B and IL29, also known as type 
III interferons, are induced by viral infections and harbour antiviral activity [194]. Type III 
IFNs are suggested to have similar intracellular response as IFN-α but with greater 
specificity as their receptors have restricted expression. It is also reported that IL28B SNP 
may have an effect on NK cell functions or the interaction between the innate and adaptive 
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immune systems. For example, the KIR2DS3 and IL28B may be predictive of chronic 
progression of HCV infection [195]. Furthermore, it was reported that the IL28B 
polymorphism, HLA-C and KIRs additively predict HCV therapy outcomes [196]. 
Moreover, it was recently reported the CC genotype is associated with higher IFN-γ 
production by NK cells during acute HCV infection, although it does not prevent chronicity 
[197]. 
1.4.4. Viral evasion of Innate Immunity  
 
As HCV infections can be spontaneously resolved in the acute phase, the innate 
immune response triggered by HCV PAMPs seems to be able to control the acute infection 
[106, 198]. However, 70% of acute infections progress to chronicity, implying that the 
virus has figured out strategies in order to escape or to counteract host defenses. Numerous 
studies have shown how several HCV proteins are capable of blocking host antiviral 
responses, ultimately leading to a chronic HCV infection.  The HCV core, E2, NS3/4A, 
NS4B and the NS5A proteins all have unique evasion mechanisms to fight the host immune 
response [15].  
Core protein: Expression of the core protein blocks IFN signaling by preventing STAT1 
tyrosine phosphorylation, which in turn blocks STAT1 dimerization with STAT2, 
preventing its translocation to the nucleus and ultimately stopping IFN signal transduction 
and ISG expression [199]. Moreover, the core protein induces the expression of suppressor 
of cytokine signalling 3 (SOCS3) which is a repressor of the JAK-STAT pathway given its 
ability to block STAT1 phosphorylation [200, 201]. It has been described that that SOCS3 
expression is increased in chronic HCV patients who are unresponsive to IFN therapy 
[201].  
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E2 : The HCV E2 protein utilizes the phenomenon of molecular mimicry as an evasion 
strategy to bypass host defense mechanisms [202]. Molecular mimicry is a mechanism 
whereby viral proteins structurally resemble host defense proteins and can behave as 
immune modulators [202].  The E2 protein contains a 12-amino acid sequence that is 
similar to eukaryotic initiation factor 2α (eIF2α) and PKR [203]. This identical domain 
blocks the phosphorylation of eIF2α ultimately repressing protein synthesis and conferring 
resistance to type I IFN treatment [204]. 
NS3/4A: In addition to its essential role in the maturation of NS proteins, in RNA 
replication and virus morphogenesis, the NS3/4A protease also possesses mechanisms to 
suppress the host antiviral system [106, 107, 198, 205, 206]. The protease contains the 
NS4A transmembrane domain and the amphipathic α-helix at the NS3 N-terminus which 
allow for the cleavage of their respective targets, MAVS and TRIF, which are fundamental 
proteins involved in the signaling cascade leading to type I IFN production [207, 208]. 
MAVS plays a critical role in the RLR pathway and is cleaved by NS3/4A at cysteine 508, 
causing the dislocation of the N-terminal part of MAVS from the mitochondria and 
therefore suppressing downstream IFN synthesis [209]. In chronically infected HCV 
patients, the cleavage of MAVS and therefore the decrease in IFN levels have been reported 
[210].  
NS4B: Stimulator of interferon gene (STING) plays an important role in the initiation of 
transcription pathways that are crucial for innate immune signalling. When stimulated with 
dsDNA, STING polymerises and facilitates the connection of TBK1 with IRF3, 
phosphorylating IFR3 and therefore activating downstream transcription of type I IFNs 
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[211]. The HCV NS4B confines STING on the ER, preventing its association with TBK, 
thereby suppressing downstream IFN signalling [212, 213].  
NS5A: This pleiotropic protein regulates the host environment such that it favours virus 
replication and persistence [214]. Moreover, NS5A binds to MyD88, a key player in the 
TLR pathway, and blocks the recruitment of IRAK1 to MyD88, thereby weakening TLR 
signalling and ultimately decreasing cytokine production [215]. 
1.4.5. Viral Evasion of Adaptive Immune Responses 
 
 Cellular immune responses are present during early HCV infection regardless of 
outcome and may even continue in chronic infection [216]. Several reports have elucidated 
that the immune response responses developed during early infection decline in chronically 
progressing patients [86, 153, 216, 217]. The majority of subjects with appreciable cellular 
immune responses during early infection exhibit loss of both breadth and magnitude of 
responses during the chronic phase of infection. The deterioration of T cell responses is not 
well understood and is believed to be a result of escape mutations. As pathogens replicate 
on the scale of hours and days and immune responses are generated over a period of weeks, 
it is suggested that escape mutations contribute to blunting the immune response efficacy 
[218]. Viral kinetic models show that up to 1012 virions are produced daily in persistent 
HCV infections [84]. This incredibly high rate of virion output, paired with the absence of 
proofreading activity of the HCV RNA polymerase amounts to common mutations in the 
viral genome. Consequently, mutations within the class I or II MHC restricted T cell 
epitopes lead to the delay in clearance of infected hepatocytes [219]. Escape mutations 
within CD8+ T cell epitope are correlated with chronicity and accounts for a key viral 
evasion mechanism. Mutated epitopes induce defective new T cell responses as they lose 
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binding and recognition capacity to their restricting MHC [220, 221]. Decreased 
recognition can result either from mutations in the epitope sequence itself or in flanking 
residues that are implicated in antigen processing [222]. Escape mutations are also 
influenced by the interaction between the host genetics and the virus. The host HLA alleles 
drive selective pressure on their corresponding epitopes. This is demonstrated when escape 
mutations convert to their wild type sequences when transferred to another person carrying 
a different HLA allele and therefore the epitope lacking selection pressure [223].  
Importantly, the extent of epitope mutations is constrained by viral fitness cost [224-228]. 
Consequently, some HLA alleles such as HLA*B27 are regarded as protective since they 
prime responses to extremely constrained epitopes that due to high fitness cost, have rare 
tendency to mutate [226, 227].  
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1.5. HCV Treatment 
1.5.1. Interferon Ribavirin Therapy 
 
In the mid-1970’s, following the identification of hepatitis A, non-A, non-B 
hepatitis (NANB) was acknowledged [2], and it was initially thought that it would have a 
negligible health impact. However, it was soon reported that NANB hepatitis mostly 
exhibited progressive disease leading to cirrhosis and potentially to liver cancer [229]. 
Therefore, coupled with efforts to identify the causative agent of NANB hepatitis, 
significant dedication was invested into discovering efficient drug therapies to hamper 
disease progression.  
The noticeable success of IFN-α therapy for hepatitis B spurred a pilot study at the 
National Institutes of Health in 1986 where NANB hepatitis patients were treated with 
recombinant IFN-α, well before the discovery of the causative agent, the hepatitis C virus 
[230]. Promising results from this study encouraged further controlled trials with IFN for 
NANB hepatitis [231, 232], and partial efficacy was concluded. The first approved regimen 
consisted of IFN-α at three doses per week for 6 months, achieving sustained virological 
response (SVR) rates of approximately 6% [231, 232]. Prolongation of the treatment to 12 
months only marginally improved SVR rates to 16%. The combination of IFN-α with a 
nucleoside-analogue antiviral, ribavirin (RBV), improved SVR rates to 34% after 6 
months, and to 42% after 12 months of treatment [233, 234].  Further steps in improving 
the half-life of IFN-α consisted in covalently coupling it to polyethylene glycol (PEG) to 
generate PEG-IFN-α. In combination with RBV, PEG- IFN-α achieved SVR rates of up to 
56% [235, 236].  
  
36 
Unfortunately, the majority of patients treated with combination IFN/RBV therapy 
experienced adverse side effects. In a trial of 1,000 patients treated with the standard dose, 
the following side effects were reported: fatigue (66%), headache (50%), nausea (42%), 
insomnia (41%), pyrexia (35%), anemia (34%), myalgia (27%), neutropenia (31%), 
depression (25%), irritability (25%) and rash (28%) [237]. Consequently, these adverse 
reactions resulted in the early interruption of therapy in 13% of participants and a dose 
decrease in 43% [237].  
1.5.1.1. Patterns of Response to IFN/RBV Therapy 
 
 The outcomes of IFN-α based therapy can be divided into three categories: SVR, 
relapse and non-response (NR). The main goal of therapy is SVR, characterized as 
undetectable HCV RNA 6 months after completion of therapy. SVR seems to represent a 
cure of infection and is correlated with lack of intrahepatic RNA and histologic recovery 
[238, 239]. Conversely, in relapsers, viremia rebounds upon completion of therapy. 
Relapse patients can be re-treated and achieve SVR often with prolonged and increase dose 
of therapy. Lastly, non-responders fail to exhibit a decrease in viral load below detection 
levels throughout and after the course of therapy [240].  
 More comprehensive characterization of treatment outcomes include early 
virological responses (EVR) and early virological clearance (EVC) defined as negative or 
≥ 2 logs decrease in HCV RNA after 12 weeks of treatment [241]. In patients who achieve 
SVR, the decline in viral load is biphasic: an early rapid reduction in HCV RNA within 2-
24 weeks due to direct blocking of virus replication [242], followed by a delayed secondary 
phase with slower reduction due to death of infected cells by immune-mediated and other 
mechanisms [243, 244].   
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1.5.1.2. Factors Determining Outcomes of Therapy 
 
The key viral factors influencing the outcome of therapy are the genotype and the 
delay in prescribing therapy [240].  In comparison to genotype 2 infection, genotype 1a 
and 1b progress to more severe liver disease and have low cure rates to IFN therapy. Among 
genotype 2 patients, 72% respond to IFN therapy, whereas only 28% of genotype 1a and 
26% of genotype 1b exhibit a response [245]. Starting treatment early during the course of 
HCV infection remarkably increases SVR rate to 88% regardless of genotype [246, 247]. 
Additional factors associated with increased SVR rates are low baseline viral loads [240] 
and increased diversity of quasispecies before start of therapy [248].  
Relevant host circumstances affecting the outcome of therapy include ethnicity and 
the lack of co-morbidities such as HIV infection, alcohol abuse, and renal diseases [240]. 
Accordingly, African Americans were reported to display fractionally lower SVR rates 
compared to Caucasians [249], and therapy was evidently less effective in patients 
suffering from HCV/HIV co-infections compared to infections with HCV alone. 
Additional factors associated with improved SVR rates include the female gender, young 
age, low body weight and better liver function [240].  
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1.5.1.2.1. IL28B SNP and outcome of therapy  
 
It was long observed that treatment outcomes with the standard PEG-IFN and RBV 
therapy had distinct outcomes among different ethnic populations. For example, African 
Americans had approximately 50% reduction in SVR rates compared to non-Hispanic 
Europeans after accounting for socio-demographic characteristics and adherence to 
treatment [249, 250].  Several GWAS studies reported SNPs surrounding the IL28B region 
to be associated with treatment outcomes [189-192].  The rs12979860 SNP is the most 
clinically relevant locus as it was strongly associated with SVR among both individuals of 
European as well as African descent. The C/C genotype is considered the favourable allele 
as about 80% of patients with this allele achieved SVR compared to 30% with the T/T 
allele. This difference in allele frequency between African and European populations 
accounts for about half of the variation in response rates to therapy [251]. 
1.5.1.3. Mechanisms of Action of IFN/RBV Therapy 
 
 The mechanism of action of IFN-α is similar to endogenous IFN signaling as 
demonstrated by experiments wherein in exogenous IFN-α administration to cell-cultures 
lacking IFN signaling pathways resulted in induction of many ISGs [252-254].  
 The exact mechanisms of action of ribavirin remain to be understood. However, a 
proposed explanation is its direct inhibition of viral replication due to an increase in the 
error rate of RdRp, resulting in early chain termination [255]. Additional suggestions 
include its action as a viral mutagen, resulting in viruses with reduced infectious capacity 
[256], modifying the Th1/Th2 ration in favour of Th1 [257], and lastly, inhibiting IL-10 
production [258].  
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Due to the considerable amount of side effects of PEG-IFN-α and ribavirin, and the 
varying efficacy of this treatment across genotypes, the success of this therapy was indeed 
limited. The combination of PEG-IFN-α and RBV was the standard therapy for HCV 
infection until the recent discovery of direct-acting antivirals (DAAs).  
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1.5.2. Direct-acting antivirals 
 
Figure 1.4: Increasing cure rates with newer antiviral therapies over the years.  Graph 
indicating the percentage of cures among patients treated with different regiments from 
1989 to 2014. (Adapted from Rehermann,  2016 [259])  
Due to the remarkable advances in the understanding of the structure and molecular 
biology of the HCV viral life cycle, coupled with the suboptimal response rates to 
IFN/RBN therapy, intense efforts were undertaken towards the discovery of novel therapies 
targeted at the virus itself. In the past decade, new DAAs have been developed and are 
currently revolutionizing therapy standards for HCV. Initially, DAAs were used in 
combination with IFN and ribavirin to improve response rates, however this regimen was 
accompanied by toxic side effects [260]. Recently, the combination of DAAs that target 
different mechanisms in the viral life cycle have shown promising results without the need 
of IFN and ribavirin, and thereby reducing negative side effects. The cure rates achieved 
  
41 
with the new DAAs surpass 90% for most populations of treated patients (Figure 1.4.) [261, 
262]. To date, the main three viral targets of DAAs are the NS3/4A protease, the NS5B 
RNA-dependent RNA polymerase and the NS5A protein [263].  
1.5.2.1. NS3/4A Protease Inhibitors 
 
The HCV NS3 is a protease with enzymatic activity, rendering it a suitable target 
for therapeutic intervention approaches. NS3 functions closely with its noncovalently 
bound cofactor NS4A that improves its protease activity. Recent crystal structures of NS3 
and NS4A have exposed a shallow cleft between N- and C-terminal domains that accepts 
the substrate [264]. The NS3/4A complex processes the HCV polyprotein at four locations, 
separating the non-structural proteins that are essential for replication.  
The first proof-of-concept study that pioneered the notion of targeting the HCV 
protease was the development of the protease inhibitor (PI), ciluprevir (BILN-2061), which 
went into phase II clinical trials [265] but was interrupted due to toxic effects in animals. 
The availability of crystal structures of NS3 in association with candidate molecules 
expedited the process of chemical synthesis, biological and structural evaluations that 
facilitated the creation of enhanced NS3 inhibitors. The structurally similar HCV PIs 
telaprevir and boceprivir were put on the market in 2011 and were the first successful class 
of DAAs to be used clinically [263].  
The first-generation PIs, despite being a breakthrough in the treatment of HCV, 
exhibit certain limitations, namely their marginal genotype specificity and their low barrier 
to resistance [263]. The appearance of mutations in positions Arg155, Ala156, and Asp168 
of the NS3 gene are the signature mutations for NS3/4A PIs, and give clear evidence for 
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the protease as a target. These resistance-conferring mutations impact the binding capacity 
of the inhibitor without affecting the binding of the natural substrate [266-268].  
1.5.2.2. NS5B Inhibitors 
 
Since NS5B is the RdRp of HCV, and uses the genome as a template for RNA 
synthesis, it is another logical target for therapeutic intervention. Crystal structures of 
NS5B describe a resemblance to the human right hand [269] with ‘thumb’, ‘finger’ and 
‘palm’ subdomains. NS5B inhibitors can be divided into non-nucleotide inhibitors (NNI) 
and nucleotide inhibitors (NI) that function at different steps of RNA synthesis [270].  
 The various NNIs, despite being chemically distinct, act prior to or at the level of 
initiation and interrupt the elongation of the RNA transcript. Drugs available on the market 
target the three sites of the NS5B. Beclabuvir targets the thumb site I, whereas Dasabuvir 
is a potent palm site inhibitor [263]. 
Contrary to NNIs, NIs compete with entering nucleoside triphosphates for binding. 
NIs are inactive prodrugs that are activated metabolically to the triphosphate form that will 
ultimately attach to the nucleotide-binding site of NS5B [270]. Sofosbuvir, a uridine 
equivalent, is the only approved drug within this category, and acts as a robust chain 
terminator. Unlike NNIs, NIs display pangenotypic activity with an elevated barrier to 
resistance [263].  
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1.5.2.3. NS5A Inhibitors 
 
 The multifunctional protein, NS5A, responsible for HCV replication and assembly 
is another major target for therapy. NS5A does not contain enzymatic activity unlike NS3 
and NS5B; therefore it was challenging to create assays for drugs targeting its functions. 
The crystal structure for NS5A is mostly unavailable; therefore cell-based replicon assays 
were instrumental in identifying its inhibitors [271]. NS5A inhibitors possess remarkable 
potencies, with EC50 amounts in the pM range. The first NS5A inhibitor on the market was 
daclatasvir, followed by the arrival of ledispavir and ombitasvir, which are used clinically 
[272]. The phenomenal potency of this class of inhibitors is attributable to the implication 
of the NS5A protein at many stages of the viral life cycle, notably, in replication and in 
assembly. The interference with the assembly of the virus-induced membranous web by 
these compounds may explain their potent effects [263].  
1.5.2.4. Success and Remaining Challenges of DAAs 
 
 The achievement of DAAs since their arrival has indeed been phenomenal with 
admirable results in clinical trials as well as in real-world studies. Future agents in late 
phase clinical trials are believed to cover the efficiency gaps in present DAAs. 
Pangenotypic NS5A blockers in combination with sofosbuvir have potential for patients 
with genotype 3 infections with cirrhosis. Moreover, patients with HIV co-infection 
respond positively to DAAs and patients with co-morbidities such as renal disease will be 
able to benefit from future regimens. For example, the future DAA grazoprevir-elbasvir 
has been tested in a dialysis population achieving SVR rates of 95% with negligible adverse 
effects [263].  
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 Evidently, the future goals of DAAs will not be to increase SVR rates necessarily, 
but rather to broaden the distribution of these drugs such that this exceptional progress can 
translate to global public health prosperity [273].  This calls for the expansion of HCV 
treatment outside specialty clinics. Moreover, an important goal is the development of 
pangenotypic therapies with a considerably shorter duration. Initiatives addressing 
treatment failures such as resistance to NS5A inhibitors is another major goal. Accordingly, 
upgraded and cheaper assays with resistance interpreting standards are essential in this 
endeavour [263]. Lastly, efforts in pricing reforms to result in more affordable regimens 
coupled with harm reduction strategies to curb new and reinfection in high-risk populations 
are essential for DAA therapy to truly cause global waves [273].   
1.5.3. Vaccine against HCV: Need and Challenges 
 
There is a major need for a prophylactic vaccine against HCV to prevent 
transmission and to reduce the global burden of disease. The abundance of research 
supporting cell mediated immunity as the major facet enabling spontaneous clearance of 
primary HCV infections gives reason to pursue this avenue for vaccine development. 
Moreover, the recent data suggesting the contribution of the role of neutralizing antibodies 
against HCV is also worth investigating and implementing in vaccine efforts [274].  
There are many hurdles facing the development of an effective HCV vaccine. First 
of all, the genetic diversity of HCV and its high rate of mutations, even within the same 
individual is an important challenge on its own. The capacity of HCV proteins to evade 
host immune responses is another challenge. Lastly, assuming that an effective vaccine is 
developed, significant public health efforts must be planned in order to deliver and 
vaccinate all populations infected or at risk of infection. For example, there is already an 
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effective vaccine against hepatitis B, however the prevalence of HBV infection worldwide 
is astounding as close to 380 million people are still infected with HBV due to poor 
vaccination campaigns in endemic countries [275]. 
1.5.3.1. Vaccine Trials 
 
There have been three major strategies for designing a vaccine against HCV.  The 
more traditional approach aims to induce neutralizing antibodies by using recombinant 
envelope proteins, an endeavour that is gaining more potential with the recent discovery of 
broadly neutralizing antibodies. Immunization with recombinant E1-E2 proteins was 
reported to generate cross-reactive nAbs implying a degree of protection upon HCV 
exposure [276-278]. Another approach involved the use of virus-like particles (VLPs) that 
contain HCV structural antigens to generate humoral and cellular responses, although they 
lacked to show humoral responses in chimpanzees [279].  
The most encouraging strategy is engineering an HCV vaccine to induce strong T 
cell responses, as the correlates of protection in HCV are T cell dependent. The proof of 
principle surrounding the idea that a prophylactic T cell vaccine against HCV may be an 
attainable goal was first demonstrated in a chimpanzee model. The method used adenoviral 
(Ad) and DNA vectors encoding for the non-structural (NS) HCV protein [280]. Following 
a heterologous viral challenge, four out of five vaccinated chimpanzees developed low-
level viremia and went on to clear the virus rapidly [280].  
To address the issue of pre-existing anti-Ad immunity in humans which can restrict 
the potency of the vaccine, a panel of replication-defective chimpanzee and human 
adenoviruses that exhibit low seroprevalence were developed to be used as vaccine vectors 
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[281, 282]. Adenovirus vectors derived from human (Ad6) as well as from chimpanzees 
(ChAd3) that encoded for the HCV NS3-NS5B polyprotein with a genetically inactivated 
NS5B polymerase were used in a human vaccine trial in healthy individuals [283]. After a 
single priming vaccination with either vector, an impressive immune response was 
achieved. The magnitude, breadth, and polyfunctionality of HCV-specific T cells were the 
most potent reported to date [284].  
Unfortunately, there were two main caveats in this trial. Firstly, when boosted with 
a heterologous Ad, T cell responses failed to reach the same levels attained after priming 
and was suggested to be a result of the induction of cross-reactive anti-Ad antibodies. 
Secondly, the major subset activated by vaccination were CD8+ T cells whereas both 
CD4+ and CD8+ T cells are crucial for viral control, as evidenced by natural history, 
genetic and depletion studies [151-153, 175, 179, 183, 274].  In order to overcome these 
obstacles, the team developed another prophylactic T cell vaccination approach based on 
heterologous virus vectors ChAd3 and modified vaccinia Ankara (MVA) [285]. This 
strategy proved to be highly immunogenic following priming and boosting, and induced 
both CD4+ and CD8+ T cells that target various HCV antigens [285]. Remarkably, the 
phenotype of CD8+ T cells induced by Ad/MVA vaccination is closely comparable to that 
induced by the very potent yellow fever and smallpox vaccines, which both confer long-
life protection [286]. This vaccine is currently in Phase II trial in a cohort of intravenous 
drug users in the United States and is registered in the ClinicalTrial.gov database (ID: 
NCT01436357) and is expected to finish in October 2017 [285].  
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1.6. Hypothesis and Objectives 
 
Only 30% of individuals acutely infected with hepatitis C virus (HCV) clear the 
virus spontaneously, whereas the majority become persistently infected and develop 
chronic liver disease. Many individuals do not know that they are infected and continue to 
transmit the virus. Hence, there is an urgent need for a prophylactic vaccine to stop HCV 
transmission. Vaccine development is hindered by our limited knowledge of the correlates 
of protective immunity in real life settings. CD8+ and CD4+ HCV-specific T cell responses 
are essential for spontaneous resolution of acute HCV. The polyfunctionality of virus-
specific CD8+ T cells characterized by the capacity to produce cytokines like IFN-γ and 
IL-2, and cytotoxicity correlated with spontaneous resolution of acute HCV and can be 
predictive of effective vaccines. Moreover, the presence of neutralizing antibodies (nAb) 
correlates with the spontaneous clearance of primary HCV infections in some individuals. 
PWIDs are at high risk of HCV exposure, infection and reinfection. We intend to 
define the correlates of protective immunity against HCV in PWIDs who have been 
exposed to the virus repeatedly but who are resistant to subsequent infections. We 
hypothesize that HCV immune PWIDs who are resistant to reinfection develop an immune 
response of high protective capacity where the magnitude (frequency), breadth (number of 
epitopes targeted) and quality (number of functions) of the HCV-specific memory T cells 
measured following resolution of primary infection will likely determine susceptibility to 
reinfection. Furthermore, the neutralizing response of nAbs will be more robust in those 
PWIDs resistant to reinfection.  
The aim of this project is to compare the protective immune responses against HCV 
in PWID who cleared a previous HCV infection spontaneously or following antiviral 
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treatment (PEG-IFN and Ribavirin) and achieved a sustained virological response (SVR) 
and remain protected from reinfection despite high risk exposure. We used peripheral blood 
mononuclear cell (PBMC) samples to perform IFN-γ enzyme-linked immunospot 
(ELISPOT) assay in re-infected versus exposed non re-infected individuals to compare the 
magnitude of the HCV-specific T cell responses. We also used flow cytometry to determine 
polyfunctionality of HCV-specific T cells in a subset of patients. Finally, we performed a 
neutralization assay using an HCV pseudoparticle assay.  
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2.1. Abbreviations  
Abs  Antibodies 
DAAs  Direct-acting antivirals  
ELISPOT  Enzyme-linked Immunospot 
FACS  Fluorescence-activated cell sorting 
HCV  Hepatitis C virus  
HCVpp  HCV pseudoparticles 
IFN  Interferon 
Ig  Immunoglobulins  
IL  Interleukin 
nAb  Neutralizing antibodies 
PBMCs  Peripheral blood mononuclear cells  
PEG  Polyethylene glycol  
PSP  Percent specific production  
PWIDs  People who inject drugs 
PY  Person-years  
RNA  Ribonucleic acid  
SFCs  Spot forming cells  
SR  Spontaneous resolver 
SVR  Sustained virological response  
TNF-α  Tumour necrosis factor-α  
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2.2. Abstract 
 
Approximately 25% of individuals acutely infected with hepatitis C virus (HCV) 
clear the infection spontaneously and develop long-lived memory T cells. Yet, these 
individuals remain susceptible to reinfections and correlates of long-term protective 
immunity remain poorly defined. Generation and maintenance of high frequency, broad, 
polyfunctional CD4+ and CD8+ HCV-specific T cell responses correlate with spontaneous 
resolution of acute primary HCV and can be predictive of long-term protection but whether 
they are key determinants of long-term protective immunity is unknown. The protective 
role of neutralizing antibodies (nAb) is also unclear. Here, we examined the magnitude, 
breadth and polyfunctionality of virus-specific T cells and the efficacy of neutralizing 
antibodies in a cohort of HCV-resolved high-risk people who inject drugs (PWIDs) 
repeatedly exposed to but resistant to reinfections. We demonstrate a correlation between 
long-lived HCV-specific T cell responses and protection from reinfection in spontaneously 
resolved and treatment resolved PWIDs. We observed long-lived HCV-specific T cell 
responses in spontaneously resolved and treatment resolved PWIDs who are protected 
against reinfection. We did not observe a difference in the nAb responses nor in the 
functionality of HCV-specific T cells. Our results suggest that protection from reinfection 
in PWIDs is associated with a sustained high frequency of HCV-specific cellular immune 
responses. 
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2.3. Introduction 
 
The hepatitis C virus (HCV) infects approximately 185 million people worldwide 
and is the leading cause of severe liver disease and hepatocellular carcinoma [1]. Despite 
the arrival of potent direct-acting antivirals (DAAs) with impressive cure rates, there 
remain substantial challenges in eradicating HCV [2]. Due to the asymptomatic nature of 
both the acute and chronic phases, infection incidences are increasing in North America 
[3] and extensive screening programs are almost non-existent in endemic countries. 
Consequently, less than 5% of the global HCV-infected population are conscious of the 
fact that they are infected [4].  
The global HCV dilemma comprises numerous challenging factors including the 
identification of infected individuals before the onset of liver disease, the occurrence of 
repeated infections, the high cost and possible resistance to therapy, and the lack of 
therapeutic strategies to cure extensively damaged livers. Moreover, reinfection following 
successful sustained virological response (SVR) is a major problem among at-risk 
individuals, especially PWIDs. It was reported that reinfection rates after SVR range from 
1 to 5 cases per 100 person-years (PY) among patients with a previous intravenous drug 
use, and augmenting to 3 to 33 cases per 100 PY in PWIDs with frequent risk behaviour 
[5]. Moreover, a recent meta-analysis demonstrated that the risk of reinfection 5 years post-
SVR is 8.2% among PWIDs and prisoners [6]. Appropriately, the prevention of chronic 
HCV may be the most effective method of reducing HCV-related morbidity and therefore, 
the development of an effective prophylactic vaccine is crucial [7]. Studies modelling the 
impact of a hypothetical HCV vaccine with 80% efficacy have predicted a significant 
impact on the incidence of persistent HCV infection and suggest it to be highly cost-
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effective [8, 9]. Unfortunately, vaccine development is hampered by our limited knowledge 
of the correlates of protective immunity in real life settings.  
There is substantial evidence of protective immunity and long-lived memory 
immune responses in people infected with HCV. A landmark study by Mehta et al. reported 
that PWIDs who were previously infected with HCV and spontaneously cleared the virus 
were 12 times less prone to develop persistent viremia as compared to HCV-naïve PWIDs 
with similar risk exposures [10]. Another study that followed a group of German women 
after an accidental common source outbreak of HCV, demonstrated that HCV-specific 
CD4+ and CD8+ T cell responses were detectable up to 20 years after the successful 
clearance of primary acute HCV while antibody responses waned [11].  Moreover, despite 
the fact that spontaneous resolvers (SR) can be subject to recurrent HCV infection upon 
subsequent exposures, the resolution of the secondary infection occurs 80% rather than 
25% of the time [10, 12-13].  
Previous research has highlighted that CD8+ and CD4+ HCV-specific T cell 
responses are essential for spontaneous resolution of acute HCV [14, 15] and are expanded 
and correlate with resolution of reinfection [13, 16]. The polyfunctionality of virus-specific 
CD8+ T cells characterized by the capacity to produce cytokines like interferon-γ (IFN-γ) 
and interleukin-2 (IL-2), tumour necrosis factor-α (TNF-α) and cytotoxicity correlated with 
spontaneous resolution of acute HCV and may be predictive of effective vaccines [17]. 
Also, polyfunctionality of CD4+ and CD8+ T cells are associated with spontaneous 
resolution of reinfection [16]. Moreover, the presence of neutralizing antibodies (nAb) 
correlates with the spontaneous clearance of primary HCV infections in some individuals 
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[18], and the presence of cross-reactive nAb correlates with reduced magnitude and 
duration of viremia upon reinfection [13].  
The aim of this study was to define the correlates of protective immunity that can 
be used to evaluate the efficacy of novel vaccines against HCV. Determining the correlates 
of protective immunity in real-life exposures such as among PWIDs is a crucial first step 
[19]. We thus examined the protective immune responses against HCV in PWID who 
cleared a previous HCV infection spontaneously or following antiviral treatment (PEG-
IFN and Ribavirin) and achieved a SVR and remained protected from reinfection despite 
high-risk exposure. We hypothesized that PWIDs who are resistant to reinfection develop 
an immune response of high protective capacity. We demonstrate that a high frequency of 
HCV-specific T cells but not nAbs are associated with long-term protection against HCV 
reinfection. 
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2.4. Materials and Methods 
 
Study Subjects 
High-risk PWIDs who had previously resolved an HCV infection were recruited via the 
Montreal Hepatitis C Cohort (HEPCO) [20]. This study was approved by the institutional 
ethics committee (protocol SL05.014) and conducted according to the Declaration of 
Helsinki. All participants signed informed consent upon enrolment. HCV resolvers were 
identified as HCV-RNA negative using the COBAS Ampliprep/COBAS Amplicor HCV 
Test, version 2.0 (Roche Molecular Systems, Inc.) (Sensitivity 50 IU/mL), anti-HCV 
antibody positive (AxSym HCV Assay [Abbott GMBH & CO, Saint Laurent, Quebec, 
Canada]). Subjects’ clinical history including history of previous infections and/or antiviral 
treatment was registered to define the date of clearance of primary infection. For subjects 
where the exact dates of primary infection and clearance were unknown, we estimated the 
time of their first infection using an epidemiological paradigm that predicts the date of 
HCV infection based on time since the beginning of injection drug use. According to Hagan 
et al. (2008) [21], it takes approximately 5 years to become infected with HCV since the 
initiation of injection drug activity. We obtained the age at initiation of drug use of our 
participants through questionnaires, and predicted the age of their primary infection 
accordingly. All subjects were followed for incidence of reinfection by retesting for HCV 
RNA every 3 months. HCV exposure and risk behaviour was assessed through 
comprehensive questionnaires. HCV reinfection was defined by an HCV RNA positive test 
after 2 negative tests at least 60 days apart. Exposed non-reinfected participants were 
defined as never having an HCV RNA positive test after a resolved primary infection (HCV 
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Ab positive or HCV RNA positive test). HCV genotyping was performed as described 
previously [22]. IFN-3 genotype was determined as previously described [23]. 
Enzyme-linked immunospot (ELISPOT) assay 
Interferon-γ (IFN-γ) enzyme-linked immunospot (ELISPOT) assay was performed against 
11 pools of overlapping peptides representing the genotype 1a (H77) polyprotein or the 
genotype 3a (K3) as previously described [24]. Peptides were obtained from the Biodefense 
and Emerging Infections Research Resources Repository (BEI Resources, Manassas, VA, 
USA). Briefly, all assays were performed in duplicates directly ex vivo on 2×105 
cryopreserved peripheral blood mononuclear cells (PBMCs). Specific spot forming cells 
(SFCs) were calculated as mean number of spots in test wells minus the number of spots 
in negative control wells and normalized to SFC/106 PBMCs. Breadth was defined as the 
number of regions of the HCV polyprotein (Core, E1, E2, etc) targeted. In many of the 
exposed non-reinfected subjects who were recruited having already resolved a primary 
HCV infection, the genotype of the primary viral strain was unavailable. In this case, we 
chose to perform the IFN-γ ELISPOT using the 1a polyprotein as this subtype is the most 
prevalent in our cohort.   
Antibodies 
The following conjugated anti-human monoclonal antibodies (Abs) were used: CD3-
Pacific Blue (clone UCHT1), CD4-BV605 (clone RPA-T4), CD8-APC-H7 (clone SK1), 
IL-2-PE (clone MQ1-17H12), IFN-γ-PECy7 (clone B27), TNFα-Alexa Fluor 700 (clone 
MAb11), CD107a-BV786 (clone H4A3). All Abs were obtained from BD Biosciences. 
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Polyfunctionality assays 
Polyfunctionality assays were performed as previously described [16] using cryopreserved 
PBMCs. Briefly, 2×106 PBMCs were incubated with anti-CD107a and either dimethyl 
sulfoxide (0.1%) as a negative control or HCV peptide pools (10 μg/mL) at 37°C in R-10 
medium (RPMI medium [Invitrogen, Carlsbad, CA] supplemented with 10% FBS). 
Following 1 h of stimulation, 10 μg/mL of brefeldin A (Sigma-Aldrich) and 6 μg/mL of 
monensin sodium salt (Sigma-Aldrich) were added, and cells were incubated for a total of 
12 h. Cells were washed with fluorescence-activated cell sorting (FACS) buffer (PBS 13 
[Wisent], 1% FBS [FBS; Sigma], 0.01% sodium azide [Thermo Fisher Scientific, 
Burlington, ON]) , stained for viability using LIVE/DEAD fixable aqua dead cell stain kit 
(Molecular Probes; Thermo Fisher Scientific) and cell surface antigens (CD3, CD4, CD8), 
and permeabilized using BD Cytofix/Cytoperm solution (BD Bioscience). Cells were then 
stained with anti-IL-2, anti-IFN-γ, and anti-TNF-α antibodies for 30 min, washed twice in 
BD Perm/Wash buffer (BD Biosciences), and fixed in FACS fix buffer. For analysis, cells 
were gated on viable CD3+, CD4+ or CD8+ T cells. Percent specific production (PSP) is 
calculated as the background-adjusted function in the presence or absence of cognate 
peptide stimulation. Cells were analysed using a standard BD LSR II instrument with 
FACSDiva software version 6.1.3 (BD Biosciences, San Jose, CA). Data files were 
analyzed using FlowJo software version 9.5 for Mac (Tree Star, Inc., Ashland, OR). 
Functionality data was analyzed with FlowJo and Boolean Gates were applied to generate 
combination gates.   
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Neutralizing antibodies assays 
HCV pseudotyped viruses (HCVpp) expressing a luciferase reporter were generated as 
previously described [25]. Two different HCV glycoproteins derived from either genotype 
1 (H77c) or genotype 5 (SA13) were used for pseudotyping. For neutralization assays, 
human hepatoma Huh7.5 cells were plated on collagen coated 96 well plates, 1 day prior 
to infection. HCVpp were diluted and premixed with purified immunoglobulins (IgG) from 
sera. IgG were purified using Melon-gel kit (ThermoFisher) according to manufacturer’s 
suggestion. The final purity of IgG from sera was monitored by SDS-electrophoresis and 
coomassie blue staining. Four descending concentrations of antibody were used: 50 µg, 
16.6 µg, 5.6 µg and 1.9 µg. Only the level of neutralization at 50 µg was shown in this 
study. The antibodies and HCVpp were preincubated at 37°C for 1 hour followed by 
addition to Huh 7.5 cells. Cells were then spinoculated at 500g, 1 hour at 37°C, followed 
by incubation another 5 hours at 37°C. The antibody-virus inoculum was then replaced 
with fresh culture media. Cells were processed 48 hours post-infection using Bright-glo 
luciferase assay system (Promega). Luminescence was measured using an Enspire plate 
reader (Perkin Elmer). The neutralization activity was calculated using the following 
formula: % neutralization = (HCVpp-HCVpp with antibody)/HCVpp ×100, where HCVpp 
represents the luciferase activity of transduced cells in absence of any antibody and HCVpp 
with antibody represents the luciferase activity of transduced cells in the presence of 
antibody isolated from volunteer’s sera. 
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Statistical analysis 
Statistical differences between groups were calculated using a two-tailed Mann–Whitney 
test. Correlations were analyzed by the Pearson test using GraphPad Prism version 5.0 (La 
Jolla, CA).  
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2.5. Results and Discussion 
Long-lived, high frequency HCV-specific T cells in exposed non-reinfected compared to 
reinfected patients (≥ 2 years) 
We sought to identify correlates of protective immunity in a cohort of HCV resolvers and 
treated PWIDs at risk of HCV reinfection identified and followed for incidence of 
reinfection as described in Materials and Methods. Subjects’ demographics and 
characteristics are listed in Tables 1 and 2. First, we compared the magnitude of the HCV-
specific T cell responses in the exposed non-reinfected group (n=27) versus the exposed 
reinfected group (n=14) using an IFN-γ ELISPOT assay as described in Materials and 
Methods. The time point studied in this cross-sectional analysis was > 6 months post-
spontaneous clearance of the primary infection or post-SVR with PEG-IFN and ribavirin 
therapy. Depending on the availability of PBMC samples, the time range varied from >6 
months to nearly 20 years post resolution of infection in some patients. We observed no 
significant difference in the magnitude of the T cell response (Figure 1A). Due to the fact 
that there may be viral rebound in the first two years after infection [12], we stratified the 
patients into two groups, <2 or ≥ 2 years post-resolution of primary infection. When these 
patients were separated into two groups, < 2 (n=8) or ≥ 2 (n=19) years post-resolution of 
primary infection, significant difference (p=0.0003) was observed (Figure 1B). The non-
reinfected individuals that had been exposed for more than 2 years had significantly higher 
HCV-specific T cell responses than individuals that had been exposed for less than 2 years. 
Moreover, a significant difference was observed between the non-reinfected and reinfected 
patients exposed for more than two years (p=0.0224) (Figure 1B). Interestingly, within the 
non-reinfected group, HCV-specific T cell responses were very long lived, ranging from 
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<2 years all the way to 24 years post resolution of primary infection (Figure 1C). This is 
consistent with a previous report wherein HCV-specific T cell responses were detectable 
up to 20 years after a common source outbreak of HCV infection [11]. Overall, this 
indicates that protection from reinfection is associated with a high frequency of long-lived 
HCV-specific T cells.  
 
Increased breadth of the HCV-specific T cell response in non-reinfected PWIDs 
Next, we examined the breadth (the number of HCV regions targeted) of the HCV-specific 
T cell responses. We observed a significantly higher (p=0.0039) T cell breadth in 
individuals exposed non-reinfected (≥ 2 years) compared to those who became reinfected 
(≥ 2 years) (Figure 2A, Supplementary Figure S1A). Taking a closer look at the HCV-
specific T cell responses to specific HCV region we noticed that all six reinfected patients 
failed to mount an immune response to the NS4A/NS4B, NS5A, as well as the NS5B 
proteins in comparison to the exposed non-reinfected patients (Figure 2C). Furthermore, in 
the exposed non-reinfected group, a similar dichotomy was observed as mentioned above. 
Within this group, those individuals protected from reinfection for ≥ 2 years exhibited 
significantly higher (p=0.0008) T cell breadth compared to their < 2 years exposed 
counterparts (Figure 2B, Supplementary Figure S1B), confirming that expanded T cell 
breadth is a crucial determinant of protective HCV immunity [26] and underscoring the 
immune dominance of the non-structural proteins [27].   
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Increased frequency HCV-specific T cell response in SVR non-reinfected PWIDs 
We also compared the protective HCV-specific immune responses among patients who 
cleared their primary infection following antiviral therapy with PEG-IFN and ribavirin and 
attained SVR. We compared the HCV-specific T cell responses using IFN-γ ELISPOT in 
exposed non-reinfected (n=19) vs. exposed reinfected (n=10) subjects. We observed a 
significantly higher (p=0.0161) HCV-specific T cell responses in the SVR exposed non-
reinfected patients compared to SVR reinfected participants (Figure 3A). Within the SVR 
non-reinfected, there was a striking dichotomy with some patients clustering together in 
the high SFC range. It is plausible that these patients were treated earlier, as we previously 
demonstrated that early IFN therapy rescues polyfunctional memory T cells [17]. 
Interestingly, there was no difference in the frequency of HCV-specific T cell responses 
when comparing the non-reinfected subjects in SVR and SR groups (Figure 3B) suggesting 
that treatment-induced protection is comparable to that of spontaneous clearance. Finally, 
there was no difference in the number of regions targeted (breadth) between the SVR non-
reinfected and SR non-reinfected patients (Figure 3C). This suggests that IFN therapy can 
rescue the breadth of HCV-specific T cells, as many regions of the HCV polyprotein were 
targeted by SVR patients (Supplementary Figure S1C).  
 
Risk exposure does not correlate with HCV-specific T cell responses 
Next, we sought to determine whether the differences observed in immune responses were 
related to differences in risk exposure where increased exposure might have resulted in 
subclinical infection(s) that boosted the immune response. We evaluated this parameter by 
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assessing the number of injections administered in the month preceding the time point 
tested. A previous study in our cohort demonstrated that the incidence of HCV infection 
increases with ≥ 30 drug injections per month [28], therefore we hypothesized that subjects 
with higher IFN-γ ELISPOT responses have higher risk exposure through increased 
number of intravenous drug injections. However, there was no apparent correlation 
between the number of injections and the HCV-specific T cell responses (Supplementary 
Figure S2). We cannot exclude inaccurate disclosure of the number or frequency of 
injections by the PWIDs in response to the questionnaire. It is also plausible that there is 
no correlation between the number of injections and the frequency of HCV-specific T cells 
for this cohort.   
Polyfunctionality does not correlate with protection from reinfection 
 Our group has previously demonstrated that polyfunctionality of HCV-specific T 
cells was a determinant of spontaneous resolution of HCV and protection upon reinfection 
[16-17]. We thus tested the polyfunctionality of HCV-specific CD4+ and CD8+ T cells by 
analyzing the production of IFN-γ, IL-2, and TNF-α, as well as expression of CD107a, a 
surrogate marker of cytotoxicity, which correlates with granzyme B, and perforin secretion 
as described in Materials and Methods. Representative flow cytometry data are depicted in 
Supplementary Figure S3. We stimulated the PBMCs from the same time point as tested 
in the IFN-γ ELISPOT. We tested four patients from each category (reinfected and non-
reinfected). These patients were selected based on the highest response observed in the 
ELISPOT assay and we used the same peptide pool(s) generating the highest ELISPOT 
response. Unfortunately, we were not able to observe substantial polyfunctionality in both 
groups (data not shown). However, when examining the individual levels of cytokine 
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production, we noticed a trend in the CD107a expression between the two groups. Non-
reinfected participants tend to have higher levels of CD107a expression in both CD8+ and 
CD4+ T cells, with higher frequency in CD4+ T cells (Figure 4A-B). Although there is no 
significant difference, this suggests that for this specific group of patients, the increased 
level of cytotoxicity may mediate protection from reinfection. Testing additional patients 
is necessary to confirm these findings, although cytotoxic CD4+ T cells have been reported 
previously in viral hepatitis and HIV-1 infection [29].  
 
Increased nAb response in non-reinfected PWIDs over time (< 2 years vs. ≥ 2 years) 
 Next, we examined the presence of neutralizing Ab responses in non-reinfected 
versus reinfected PWIDs using two different HCVpp as described in Materials and 
Methods. Consistent with our ELISPOT data, we observed significantly higher percent 
neutralization in PWIDs non-reinfected ≥ 2 years (Figure 5A) compared to those non-
reinfected for < 2 years. Interestingly, this difference was much more prominent when 
neutralization was tested against the heterologous genotype 5 (SA13) strain, rarely seen in 
North America (Figure 5B). This may suggest a cross-reactive nAb response among those 
non-reinfected, as there is approximately 30-35% divergence in the nucleotide sequences 
between the two different genotypes.  These results suggest that nAbs that develop upon 
clearance of primary infection, tend to increase in titer or neutralizing efficacy with time 
as PWIDs continue to be exposed to HCV and maybe to subclinical infections.  Given that 
both groups exhibited similar risk exposures, it was not surprising that there was no 
statistically significant difference in the nAb response between reinfected and non-
reinfected individuals. This preliminary data suggest that nAbs are not associated with 
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protection from reinfection in this cohort but require further validation with a larger cohort. 
Nevertheless, there may be other benefits of these nAbs. Perhaps these long-lived humoral 
responses may play a role in the outcome of a subsequent infection, just as reported in a 
previous study wherein the presence of nAb response during reinfection was associated 
with lower duration and magnitude of viremia [13]. Comparing our results to the study by 
Takaki et al. where women who spontaneously cleared a common source outbreak of HCV 
had undetectable levels of HCV-specific Abs 18-20 years after resolution [11], suggest that 
in our cohort of PWIDs, long-term frequent risk behavior may be associated with exposure 
to subclinical HCV infection and stimulating the generation of long-lived HCV-specific 
nAbs. This suggests that among these PWIDs, there may have been HCV exposures that 
did not lead to productive infections or may have been blunted rapidly.  Additional analyses 
on the viral load and infection outcomes with a closer follow-up interval need to be 
examined to confirm these possibilities. Moreover, it is important to note that there are 
much fewer participants in the reinfected group, thus, recruiting additional reinfected 
patients is crucial in further validating our results.  
 
No correlation between nAbs and T cell responses 
Next, we examined whether nAb responses correlated with HCV-specific T cell 
responses using the Pearson R correlation. Our results demonstrate no significant 
correlation in neither non-reinfected (p=0.5493) nor reinfected (p=0.7902) individuals 
(Supplementary Figure S4). The same is true when all participants were combined together 
(p=0.6274) (Supplementary Figure S4). This suggests PWIDs with high HCV-specific T 
cell responses do not necessarily have high nAb responses as well. 
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Concluding Remarks 
Overall, we observed a correlation between long-lived HCV-specific T cell 
responses in exposed non-reinfected for ≥ 2 years and protection from reinfection in 
spontaneously resolved individuals. A trend in higher CD4+ and CD8+ T cell cytotoxic 
activity as characterized by the expression of CD107a is observed among the non-
reinfected, however it is not-significant, most likely due to very few patients tested. 
Furthermore, increased nAb responses with time (< vs ≥ 2 years) among non-reinfected 
PWIDs suggest that humoral responses may be enhanced by subclinical exposure to HCV 
via drug use. However, the non-significant difference in the nAb response between the non-
reinfected and reinfected patients suggest that nAb are not key determinants of protection 
but may play a complementary role to T cell responses, such as in the reduction in 
magnitude and duration of viremia upon reinfection, as reported previously [13]. SVR 
patients protected from reinfection have significantly higher HCV-specific T cells 
responses compared to SVR reinfected patients suggesting that immune responses restored 
by antiviral therapy can be protective. Altogether, our results suggest that protection from 
reinfection in PWIDs is associated with a good HCV-specific T cell response but the role 
of nAbs remains unclear.  Further testing with additional patients from other cohorts is 
important to broaden our understanding of the protective immunity in PWIDs exposed but 
protected from reinfection.  
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2.8. Tables 
 
Table 1. Clinical Characteristics of Spontaneously Resolved Subjects 
 
Non-reinfected 
n=27 
Reinfected 
n=14 
Sex (M/F) 
 
22/5 12/2 
Mean Age (years) 
 
45 42 
HCV Genotype 
(1/3/NA) 
8/1/18 5/2/7 
IL28B (CC/CT/TT/NA) 
 
15/7/1/4 6/6/2/0 
Number of Injections during Past Month 
(≤30/>30/NA) 
14/13/0 4/10/0 
               NA: Not Available 
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Table 2. Clinical Characteristics of Treated (PEG-IFN & RBV) Subjects 
 
Non-reinfected 
n=19 
Reinfected 
n=10 
Sex (M/F) 
 
18/1 9/1 
Mean Age (years) 
 
46 45 
HCV Genotype  
(1/3/2b/NA) 
 
7/4/1/7 5/5/0/0 
IL28B 
(CC/CT/TT/NA) 
 
4/10/1/4 7/3/0/0 
Number of Injections during Past Month 
(≤30/>30/NA) 
13/6/0 6/4/0 
               NA: Not Available 
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2.9. Figures 
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Supplementary Figure S3. Representative Flow cytometry gating for intracellular cytokine staining on 
stimulated (SEB) and non-stimulated CD8+ T cells. Experiments were performed directly ex vivo on 
cryopreserved PBMC samples. Gating was done on live, single, CD3+ and CD8+ T cells. The above gates were 
applied to determine the percentage of TNF-α, IL-2, IFN-γ, and CD107a-producing cells.  
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Chapter 3: Discussion 
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Discussion  
Results from our cross-sectional study comparing PWIDs exposed to HCV but non-
reinfected to those who are reinfected allowed us to better understand the correlates of protective 
immunity against HCV. Despite the limited availability of samples and confounding factors 
associated with studies in PWIDs, we were able to organize our data to see interesting trends that 
will help in understanding the dynamic nature of HCV immunity in a “real-life” setting.  
Overall, we see an association between long-lived HCV-specific T cell responses and 
protection from reinfection in spontaneously resolved individuals. Individuals resistant to a 
reinfection for more than 2 years post-clearance of a primary infection have significantly higher 
frequency (p=0.0224) and breadth (p=0.0039) of HCV-specific T cell responses as compared to 
individuals who are reinfected (Figure 1B and 2A). Although not significant, a trend in higher 
CD4+ and CD8+ T cell cytotoxic activity as defined by the expression of CD107a was observed 
among non-reinfected individuals. SVR patients protected from reinfection have significantly 
higher (p=0.0161) HCV-specific T cells responses compared to SVR reinfected patients 
suggesting that immune responses restored by antiviral therapy can be protective (Figure 3A). 
Overall, our results suggest that protection from reinfection in PWIDs is associated with a good 
HCV-specific T cell response. 
3.1. Long-lived, high frequency HCV-specific T cells in exposed non-reinfected patients 
A noteworthy observation in our exposed non-reinfected subjects is that HCV-specific T 
cell responses were detectable up to 20 years post-clearance of primary infection. This is similar 
to a previous study where a group of women infected through a common source outbreak also had 
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detectable HCV-specific T cell responses up to 20 years after the clearance of primary infection 
[183].  
We examined the association between the frequencies of injection use with the magnitude 
of HCV-specific T cell responses. We did not observe any correlation, suggesting that the 
frequency of drug use is not directly influencing the T cell responses. Coupling this data with a 
previous report of the group of women accidentally infected during a common source outbreak 
[183], suggest that HCV-specific T cell responses are long lived independent of drug use activity. 
However, we cannot exclude the fact that despite our regular follow-up every 3 months, we could 
have missed short episodes of rapidly clearing viremia. 
One interesting phenomenon that was observed in our non-reinfected subjects, whereby 
those exposed and resistant to reinfection for ≥ 2 years had significantly (p=0.0003) higher 
magnitude of HCV-specific T cell responses compared to those non-reinfected (< 2 years) is 
intriguing. It would be interesting to follow these individuals longitudinally to determine the 
dynamics of their T cell response to determine when exactly the T cell response surges. A plausible 
explanation that we cannot rule out is an undetected incident of reinfection that cleared rapidly. 
However, even if a reinfection occurred and was cleared rapidly, it suggests that the presence of 
robust memory HCV-specific T cell response was responsible for clearance. It is also possible that 
memory T cells in the context of HCV take more than 2 years to stabilize beyond the contraction 
phase of the immune response and during the first two years, individuals may be more susceptible 
to reinfection. 
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3.2. Increased frequency of protective IL28B genotype in non-reinfected subjects 
 When considering the IL28B SNP among non-reinfected versus reinfected individuals we 
see an interesting observation. Among non-reinfected subjects, 56% (15/27) have the protective 
CC genotype, whereas among the reinfected only 43% (6/14) have this genotype. It is true that 
there are fewer participants in the reinfected group, however this observation is in line with 
previous research that shows that the favourable CC allele is associated with spontaneous 
resolution of primary HCV infection, response to therapy and re-clearance upon reinfection [189-
192, 287]. No doubt, many more participants need to be recruited to make a correlation between 
the CC genotype and protection from reinfection, however our results show an interesting trend 
that deserves further investigation. 
3.3. Increased cytotoxic profile of HCV-specific T cells in non-reinfected subjects 
 An interesting observation in our study is the increased expression of the surrogate marker 
of cytotoxicity, CD107a, in CD4+ T cells as compared to CD8+ T cells. This may seem unusual, 
however several studies have reported the existence of cytotoxic CD4+ T cells in chronic viral 
infections. For example, cytotoxic CD4+ T cells as characterized by the secretion of perforin have 
been reported in HIV-1, Hepatitis D Virus (HDV), HBV and HCV infections [288]. Interestingly, 
it was reported that perforin-positive CD4+ T cells decreased upon spontaneous clearance of HCV, 
and remained stable in chronically evolving HCV. A longitudinal follow-up for our patients would 
be necessary to further elucidate the role of cytotoxic CD4+ T cells in protection against HCV 
reinfection.  
Additionally, it would be interesting to consider the individual secretion of granzyme B 
and perforin to see if it correlates with CD107a expression.  Furthermore, to validate that CD107a+ 
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CD4+ T cells are indeed cytotoxic, standard 51Cr release or similar direct cytotoxicity assays can 
be performed whereby target cells labelled with 51Cr are incubated with CD4+ effector T cells at 
varying effector to target ratios [289]. A correlation between CD107a expression and cytotoxicity 
would further validate our findings.   
 
3.4. SVR-associated protection from reinfection 
 Reinfection following successful SVR is a major problem among at-risk individuals, 
especially PWIDs. Due to the high rates of reinfection after SVR, we were interested in examining 
if there was a difference in the HCV-specific memory response in reinfected versus non-reinfected 
patients after SVR.  
According to our findings, the increased magnitude (p=0.0161) of HCV-specific T cell 
responses post-SVR is an important factor in protection from reinfection against HCV (Figure 3A). 
When comparing the magnitude of HCV-specific T cell responses in treated (SVR) versus 
spontaneously cleared participants we observe no statistical significance (Figure 3B) indicating 
that there is similar protection. In other words, spontaneously resolving an HCV infection seems 
to be equally as effective in protection from reinfection as getting treated using IFN-α and RBV 
therapy. However, we did not normalize for risk factors and our sample sizes were small. It would 
be important to recruit more participants to get a more accurate representation.  
Previous research by our group demonstrated the early therapeutic intervention using the 
standard PEG-IFN and RBV therapy rescued polyfunctional HCV-specific T cells. Importantly, 
these polyfunctional T cells were phenotypically and functionally comparable to memory T cells 
in spontaneously resolving patients [156]. We suggest that the non-reinfected patients with higher 
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magnitude of HCV-specific T cell responses had an early therapeutic intervention that rescued 
polyfunctional memory T cells. Unfortunately, we were not able to verify the exact times of 
treatment, as this information was not available as treatment was done before recruitment into the 
cohort.  
Our results suggest that the old-generation antiviral therapy, PEG-IFN and RBV, may play 
an important role in conferring protection from intravenous drug use-associated reinfection. We 
hypothesize that those PWIDs with an early therapeutic intervention are the ones with the highest 
HCV-specific T cell responses that are responsible for this protection.  
With the arrival of newer, more potent DAAs, it will be interesting to follow-up patients 
treated with these new drugs and assess the rate of reinfection, and potentially compare them with 
the older generation IFN-based therapy. Indeed, novel data suggest that DAAs are able to restore 
certain aspects of HCV-specific immunity [290]. Furthermore, it would be interesting to 
investigate the role of nAb in this group of patients to assess if they confer a protective role. 
 
3.5. Increased antibody neutralization among non-reinfected subjects over time 
Our results from the antibody neutralization pseudoparticle assay demonstrate that 
individuals resistant to a reinfection for a long time (≥ 2 years) have significantly higher (p=0.02 
and p=0.0005) level of antibody-mediated neutralization compared to those exposed for less than 
2 years against both genotype 1 (H77) and the genotype 5 (SA13) strains, respectively. However, 
no significant difference was observed between the reinfected and non-reinfected subjects. We 
also observed that there was a greater neutralization response against the genotype 5 strain 
compared to the genotype 1 strain which is the predominant strain in our cohort. This data seems 
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to suggest that the presence of nAb response does not protect against reinfection, however it may 
play a complementary role, perhaps in reducing the magnitude and duration of a secondary 
infection as reported previously [274]. However, further experiments examining the viral load and 
duration of the secondary infection is necessary to confirm this. More importantly, recruiting 
additional reinfected patients and carrying out nAb assays is crucial in adding more strength to the 
data as the reinfected group is smaller compared to the non-reinfected group. 
Looking more closely at the types of antibodies and their specificities would enable further 
understanding of the differences between reinfected versus non-reinfected participants. The 
literature on the role of Fc-mediated antibody activity in controlling HCV is limited and only a 
single paper reports that ADCC can be mediated by antibodies targeting the E2 protein [291]. 
Finally, as there are more non-reinfected individuals than reinfected individual in our cohort, 
recruiting additional patients to the reinfected category will provide more conclusive data.  
Strengths and Limitations 
The greatest strength of this project is the access to rare and unique documented cases of 
HCV infection and reinfection among a high-risk cohort. Obtaining access to these patient samples 
allowed us to study the correlates of HCV immune protection in a real-life setting. Since this cohort 
is comprised of many marginalized and, often, homeless individuals, there are a number of 
challenges associated with working with this population. Firstly, it is sometimes difficult to contact 
the participants if they miss an appointment to donate blood, thereby making it challenging to have 
a longitudinal approach to the study. Ideally, a longitudinal approach would have been more 
informative, however, due to unavailability of blood samples at exactly the same time-points in 
the infection for each participant and the loss to follow-up in this cohort, this was not feasible. 
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Secondly, working with patient samples, we are restricted to the number of parameters we can test, 
as there is a limited supply of PBMCs, requiring resourcefulness and careful planning.  
The ELISPOT technique is a very powerful and sensitive technique that allows for the 
detection of antigen-specific cells. It also allows for the quantification of the number of regions 
targeted as overlapping peptides can be added into separate pools. This technique is even more 
sensitive than flow cytometry as we were able to detect IFN-γ producing cells in ELISPOT, and 
not with flow cytometry.  
The HCVpp neutralization assay is based on lentiviral particles expressing the HCV Env 
proteins, and is therefore not a real infectious virion.  In our study, the Env glycoproteins were 
derived from only 2 different viral genotypes (Genotype 1a and 5). Optimally, it would have been 
more relevant to our cohort to have an HCVpp expressing the Env glycoproteins of genotype 3 
since it is prevalent in our cohort. A more authentic system is the HCV cell culture (HCVcc) 
particles which are derived from the JFH-1 strain that can generate infectious particles. In the 
future it would be interesting to use this HCVcc system to study in-depth the neutralizing activity 
in patient serum against genetically diverse viruses.  
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Conclusions 
We were able to demonstrate a correlation between long-lived HCV-specific T cell 
responses and protection from reinfection in spontaneously resolved individuals. Individuals 
resistant to a reinfection for more than 2 years post-clearance of a primary infection have 
significantly higher frequency and breadth of HCV-specific T cell responses as compared to 
reinfected individuals. We demonstrate that there is an increase in the nAb responses over time 
(<2 years vs ≥ 2 years) among the non-reinfected individuals, however this difference is not 
significant when compared to the reinfected individuals. This may be due to the very low number 
of participants in the reinfected category, and further participants should be recruited to validate 
these findings.  Moreover, there is a trend of higher CD4+ and CD8+ T cell cytotoxic activity as 
defined by the expression of CD107a among the non-reinfected subjects, however this difference 
was not significant. Furthermore, our results suggest that the old-generation antiviral therapy, 
PEG-IFN and RBV, may conferring protection from intravenous drug use-associated reinfection. 
We hypothesize that those PWIDs with an early therapeutic intervention are the ones with the 
highest HCV-specific T cell responses that are responsible for this protection.  
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Future Directions 
 
The unique group of non-reinfected patients with extremely robust T cell responses as well 
as substantial neutralizing antibody responses are worthy of further experimentation. Further tests 
to determine other important parameters that influence antibody responses such as Tfh cells are 
worth investigating.  Moreover, as some reinfected individuals also displayed high HCV-specific 
T cell responses, examining markers of T cell exhaustion, such as TIGIT, PD-1, CTLA-4 will 
perhaps help elucidate the differences in the quality of the T cell response.  
As we were unable to observe substantial polyfunctionality in our patients, further 
optimization of protocols should be undertaken to obtain more representative results. Moreover, 
as we noticed increased cytotoxicity as characterized by the expression of CD107a, it would be 
interesting to look at individual perforin and granzyme secretion by intracellular cytokine staining. 
In addition, direct cytotoxicity assays (ex. 51Cr release) would further confirm our observations. 
Furthermore, an in depth longitudinal follow-up of the reinfected and non-reinfected patients will 
also be beneficial in elucidating the dynamics to the T cell and B cell response since we observed 
a significantly higher HCV-specific T cell response after ≥ 2 years compared to < 2 years post-
resolution of primary infection. Lastly, as we had limited numbers of participants in our cohort, 
collaborations with similar cohorts would allow us to expand the number of subjects to ultimately 
have a better understanding of protective immunity against HCV.  
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